<SEC-DOCUMENT>0001129928-22-000085.txt : 20221107
<SEC-HEADER>0001129928-22-000085.hdr.sgml : 20221107
<ACCEPTANCE-DATETIME>20221107083837
ACCESSION NUMBER:		0001129928-22-000085
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221107
DATE AS OF CHANGE:		20221107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		221363875

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>q32022form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6d10719e6d8843ef8a8d2552dd3e5e9e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;  </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form 6-K</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Foreign Private Issuer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Rule&#160;13a-16 or 15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the month of November 2022 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number 001-38512</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Suite&#160;804, 322 11th Avenue SW</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Calgary, Alberta, Canada T2R 0C5</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:38.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.251%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.725%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;20-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#254;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;40-F&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)&#58;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div id="i6d10719e6d8843ef8a8d2552dd3e5e9e_4"></div><div style="-sec-extract:summary;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">INCORPORATION BY REFERENCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s Management&#8217;s Discussion and Analysis of Operations and Financial Condition for the Three and Nine Months Ended September&#160;30, 2022, included as Exhibit&#160;99.2 of this Form&#160;6-K and the Interim Financial Statements as of and for the Three and Nine Months Ended September&#160;30, 2022, included as Exhibit&#160;99.1 of this Form&#160;6-K (Commission File No.&#160;001-38512), furnished to the Commission on&#160;November&#160;7, 2022, are incorporated by reference into the Registrant&#8217;s Registration Statement on Form&#160;F-10 (Commission File No. 333-265510).</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:16.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT<br>NUMBER</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DESCRIPTION</font></td></tr><tr><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex991-interimfsseptember30.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. </a><a href="ex991-interimfsseptember30.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S</a><a href="ex991-interimfsseptember30.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">eptember</a><a href="ex991-interimfsseptember30.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> 30, 2022 Interim Financial Statements</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex992-q32022mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Oncolytics Biotech&#174; Inc. </a><a href="ex992-q32022mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">September</a><a href="ex992-q32022mda.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> 30, 2022 Management Discussion &#38; Analysis</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex993-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of </a><a href="ex993-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">September</a><a href="ex993-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> 30, 2022 interim filings - CEO</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="ex994-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certification of </a><a href="ex994-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">September</a><a href="ex994-q32022certificationx.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> 30, 2022 interim filings - CFO</a></font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November&#160;7, 2022</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;Kirk Look</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991-interimfsseptember30.htm
<DESCRIPTION>EX-99.1 2022 THIRD QUARTER INTERIM FINANCIAL STATEMENTS
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7929e2ff54074844a60ef956d8d6b8ed_4"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Condensed Interim Consolidated Financial Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(unaudited)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">September&#160;30, 2022 and 2021</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"></td><td style="width:67.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at </font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (note 4)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,362,063</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262,044&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables (note 8)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">496,855</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">866,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,346,353</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775,800&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,205,271</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,903,899&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">379,700</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392,041&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">374,006</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584,251&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,958,977</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880,191&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,321,251</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987,870&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 8)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,279&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">294,864</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293,672&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (notes 5(b), 10)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50,030</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,017&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,666,145</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689,838&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability </font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730,287</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730,287&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">165,918</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361,081&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,562,350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,781,206&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 8)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity </font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 5)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized&#58; unlimited</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued&#58; September&#160;30, 2022 &#8211; 58,706,442 </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2021 &#8211; 55,043,789</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,068,304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348,183&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants (note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (notes 5, 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,301,814</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,161,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">722,631</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,738&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(409,696,122)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,415,609)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity </font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,396,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,098,985&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,958,977</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880,191&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (notes 6, 12, 13)</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,678,496</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278,705&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,590,464</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,240,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative (notes 6, 12, 13)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,381,413</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,312&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,825,659</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,539,188&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,059,909)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,155,017)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(18,416,123)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,780,088)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Change in fair value of warrant derivative (note 10)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,677)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,309</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,405)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange gain</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,525,514</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,212,070&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,939,468</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,164&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">146,487</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,740&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214,254</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,457&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,404,585)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,864,991)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,253,092)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,545,872)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,598)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,151)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,421)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,151)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,407,183)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,872,142)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,280,513)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,553,023)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income items that may be reclassified to net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">269,390</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,907&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">334,893</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net comprehensive loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,137,793)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,777,235)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(15,945,620)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,546,798)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 7)</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 7)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,325,075</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,960,650&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,529,973</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,003,541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:22.5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"></td><td style="width:35.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.793%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,022,356&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,225&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367,111,330)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,752,993&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,553,023)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,546,798)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (notes 5, 6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,697&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,747)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (notes 5, 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413,282&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413,282)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement (note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697,238&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697,238&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247,078)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2021</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,166,760&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,185,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,450&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(385,664,353)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,711,992&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,161,103&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387,738&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393,415,609)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,098,985&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,893&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,280,513)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,945,620)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (notes 5, 6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,487)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,083&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (notes 5, 6)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,388&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,388)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of equity warrant agreement (note 5)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,617,570)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; Agreement (note 5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,552&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,552&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (note 6)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629,016&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629,016&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 5)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,389)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,389)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2022</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,068,304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,301,814</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">722,631</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(409,696,122)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,396,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in Canadian dollars)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:65.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.120%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the period</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(16,280,513)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,553,023)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (note 12)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,588</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,979&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use-assets (note 12)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,111&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation (notes 6, 12, 13)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,629,016</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697,238&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,959</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,848&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange (gain) loss </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,663,988)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,925&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (note 10)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,309)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 11)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,448,590)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775,818)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,416,436)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,098,335)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,740)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,236)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in investing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,740)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,236)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options (note 6)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,083</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,950&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrant derivative (note 5)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,946&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from &#34;At the Market&#34; equity distribution agreement (note 5)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,602,163</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,920,993&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(279,405)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285,502)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,334,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,067,387&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,137,335)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757,816&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,262,044</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,219,574&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,237,354</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,362,063</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,087,369&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_31"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_34"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 1&#58; Nature of Operatio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ns</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our program in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer to a phase 3 licensure-enabling study. In addition, we are exploring gastrointestinal registration program opportunities through our GOBLET platform study.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. As at September&#160;30, 2022, we had an accumulated deficit of $409,696,122. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and through the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2022, we had cash and cash equivalents of $32,362,063, and we believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent to which external factors outside of our control, including those related to the coronavirus infectious disease 2019 (&#8220;COVID-19&#8221;) pandemic and the global political conflict in Ukraine, may directly or indirectly impact our business, results of operations and financial condition, including our ability to finance our operations, expenses, clinical trials, and research and development costs, will depend on future developments that are evolving and highly uncertain. We considered the potential impact of these events, including global supply chain disruptions, inflation, and rising interest rates, when making certain estimates and judgments relating to the preparation of these condensed interim consolidated financial statements. While there was no material impact to our condensed interim consolidated financial statements as at and for the nine months ended September&#160;30, 2022, our future assessment of the magnitude and duration of COVID-19 and conflict in Ukraine, as well as other factors, could result in a material impact to our consolidated financial statements in future reporting periods.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 2&#58; Basis of Presentation</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) and in compliance with International Accounting Standard (&#34;IAS&#34;) 34 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as issued by the International Accounting Standards Board (&#34;IASB&#34;).</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed interim consolidated financial statements for the three and nine months ended September&#160;30, 2022, were authorized for issue in accordance with a resolution of the Board of Directors on November&#160;3, 2022.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed interim consolidated financial statements have been prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notes presented in these condensed interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these condensed interim consolidated financial statements </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be read in conjunction with our most recent annual audited consolidated financial statements for the year ended December&#160;31, 2021.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at September&#160;30, 2022 and are presented in Canadian dollars, our functional currency.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of estimates</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed interim consolidated financial statements in conformity with IFRS requires management to make judgments, estimates, and assumptions that affect the amounts reported in the condensed interim consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_40"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 3&#58; Significant Accounting Policies</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies applied in these condensed interim consolidated financial statements are the same as those applied in our audited consolidated financial statements for the year ended December&#160;31, 2021.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and example to help entities apply materiality judgements to accounting policy disclosures. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduces a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The adoption of this standard is not expected to have a material impact on our consolidated financial statements. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrows the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments apply to annual reporting periods beginning on or after January 1, 2023, with earlier application permitted. The amendments apply prospectively to transactions that occur on or after the beginning of the earliest comparative period presented. We are assessing the impact of adopting this standard on our consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_43"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 4&#58; Cash Equivalents </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of interest-bearing deposits with our bank totaling $29,949,747 (December&#160;31, 2021 &#8211; $39,901,509).&#160;&#160;The current annual interest rate earned on these deposits is 2.80%  (December&#160;31, 2021 &#8211; 0.45%).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_49"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 5&#58; Share Capital</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824,172&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,771&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,833&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(c)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168,071&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,616&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256,280)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348,183&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,388&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to &#34;At the Market&#34; (ATM) equity distribution agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)(d)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,613,760&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,159,552&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557,389)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2022</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,706,442</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,068,304</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$40,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the nine months ended September&#160;30, 2021, we sold 5,685,097 common shares for gross proceeds of US$18,503,188 at an average price of US$3.25. We received, net of commissions of US$555,096, proceeds of US$17,948,092. In total, we incurred share issue costs (including commissions) of $707,421. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On August 16, 2019, pursuant to an underwritten public offering, 4,619,773 units were sold at a purchase price of US$0.81 per unit. Each unit included one common share with a fair value of US$0.54 and one common share purchase warrant with a fair value of US$0.27. These warrants were classified as a financial liability. Each common share purchase warrant entitled the holder to purchase one common share at an exercise price of US$0.90 until August 16, 2024. No warrants were exercised during the nine months ended September&#160;30, 2022. As at September&#160;30, 2022, there were 64,035 warrants remaining (December&#160;31, 2021 - 64,035). During the nine months ended September&#160;30, 2021, our share capital included fair value of $455,670 in addition to gross proceeds of US$181,550 for the 201,722 warrants that were exercised. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. During the nine months ended September&#160;30, 2022, we sold 2,719,770 (September&#160;30, 2021 - 2,715,932) common shares for gross proceeds of US$4,560,307 (September&#160;30, 2021 - US$8,654,892) at an average price of US$1.68 (September&#160;30, 2021 - US$3.19). We received, net of commissions of US$136,809 (September&#160;30, 2021 - US$259,647), proceeds of US$4,423,498 (September&#160;30, 2021 - US$8,395,245). In total, we incurred share issue costs (including commissions) of $209,278 (September&#160;30, 2021 - $539,657). This sales agreement was terminated on June 16, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the nine months ended September&#160;30, 2022, we sold 893,990 common shares for gross proceeds of US$1,082,928 at an average price of US$1.21. We received, net of commissions of US$32,488, proceeds of US$1,050,440. In total, we incurred share issue costs (including commissions) of $348,111. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Warrants</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold for gross proceeds of $11,511,500. Each unit included one common share and one common share purchase warrant, which were classified as equity. These warrants expired on June 1, 2022, and were transferred to contributed surplus on the interim consolidated statement of financial position upon expiry. There was no cash flow impact as a result of the warrant expiry. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding equity warrants&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,443,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,617,570&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,443,500)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,617,570)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at September 30, 2022</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_55"></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 6&#58; Share-Based Compensation</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock option activity for the nine months ended September&#160;30, 2022 and 2021 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.278%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br>$</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,334,420</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.53</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">292,500</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.39</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,267,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(62,962)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.83</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88,945)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(255,894)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.36</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,156)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.53</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,333)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.45</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96,493)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,299,731</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.23</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841,961&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,529,741</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.44</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,236,960&#160;</font></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at September&#160;30, 2022&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.528%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.54 - $1.89</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002,498&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.02</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.39</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,998&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.90 - $3.05</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011,942&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.12</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.36</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577,792&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06 - $3.29</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016,659&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.30 - $3.40</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457,501&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.41 - $40.00</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695,291&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.13</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.01</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">677,791&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.10</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,299,731&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.23</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529,741&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.44</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from one to three years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the nine months ended September&#160;30, 2022 and 2021 were determined using the following weighted average assumptions&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.93%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected hold period to exercise</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.54%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.37%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$0.92</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.27</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Incentive Share Award Plan</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Share Units (&#34;RSUs&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted RSUs to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either immediately, on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also granted RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three-year period. Our RSU activity for the nine months ended September&#160;30, 2022 and 2021 was as follows&#58;</font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:63.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of the period</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,560</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(40,560)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,388)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of the period</font></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,230&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reserved 5,870,644 common shares for issuance relating to our outstanding equity compensation plans. Our share-based compensation expense was $499,924 and $1,629,016 for the three and nine months ended September&#160;30, 2022, respectively (September&#160;30, 2021 - $1,006,920 and $2,697,238, respectively).  </font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_61"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 7&#58; Loss Per Common Share</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated using net loss for the period and the weighted average number of common shares outstanding for the three and nine months ended September&#160;30, 2022 of 58,325,075 and 57,529,973, respectively (September&#160;30, 2021 - 54,960,650 and 53,003,541, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the period has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_73"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 8&#58; Commitments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments totaling approximately $16,800,000 for activities mainly related to our clinical trial, manufacturing, and translational science programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitments include the committed payments related to our co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (&#34;Pfizer&#34;), known as BRACELET-1, as this phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. As at September&#160;30, 2022, we recorded US$278,268 ($381,421) (December 31, 2021 - US$616,855 ($782,049)) in other receivables related to BRACELET-1 cost from Pfizer per the terms of the collaboration agreement and nil (December 31, 2021 - US$277,866 ($352,279)) in other liabilities representing future trial costs to be incurred.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a clinical trial agreement entered into with the Alberta Cancer Board (&#8220;ACB&#8221;), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product.&#160;We agreed to repay the ACB in annual installments in an amount equal to the lesser of&#58; (a) 5% of gross sales of a specified product&#59; or (b) $100,000 per annum once sales of a specified product commence.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at September&#160;30, 2022 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:81.719%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,272&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,244&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,516&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_76"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 9&#58; Capital Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property protection.&#160;We include shareholders' equity and cash and cash equivalents in the definition of capital.  </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:63.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.182%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.390%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,362,063</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262,044&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,396,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,098,985&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments and contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be affected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our US$65,000,000 ATM equity distribution agreement in June 2022 (see Note 5). We use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital and better manage our cash resources. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2022.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_79"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 10&#58; Financial Instruments</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative.&#160;As at September&#160;30, 2022, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at September&#160;30, 2022, the fair value of our warrant derivative was $50,030 (December&#160;31, 2021 - $56,017). We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &#160;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study (see Note 8) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $188,000.&#160;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at September&#160;30, 2022 are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollars </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,377,467&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345,402)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705,472)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,032,065&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705,472)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 9. Accounts payable and accrued liabilities are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_82"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 11&#58; Additional Cash Flow Disclosures</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.198%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">369,200</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161,658)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2,570,553)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(827,368)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,333,381</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,236&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(352,279)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,985)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(228,339)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,043)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,448,590)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(775,818)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.814%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">278,213</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,305&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,795&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_88"></div><hr style="page-break-after:always"><div style="min-height:99pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in Canadian dollars, except share amounts) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font></div></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 12&#58;  Components of Expenses</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,363,948</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,674,955</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,576,886&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650,584</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,994&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,670,765</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277,050&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,681</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,324&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415,834</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524,763&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109,941</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,831&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250,204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,515&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,187,751</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,592,412</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">273,700</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">910,973</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470,569&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,505&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,321</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,678,496</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278,705&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,590,464</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,240,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,370,501</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700,773&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,787,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066,646&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">686,870</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,717&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,027,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226,224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,299&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">718,043</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226,669&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,989</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,588</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,829</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,434&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,111&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,381,413</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,312&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,825,659</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,539,188&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development personnel-related expenses included employee compensation and benefits of $1,187,751 and $3,552,456 for the three and nine months ended September&#160;30, 2022, respectively (September&#160;30, 2021 -  $946,890 and $2,832,149, respectively). </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our general and administrative office expenses included employee compensation and benefits of $572,325 and $1,720,664 for the three and nine months ended September&#160;30, 2022, respectively (September&#160;30, 2021 - $512,412 and $1,560,362, respectively).</font></div><div style="text-align:center"><font><br></font></div><div id="i7929e2ff54074844a60ef956d8d6b8ed_94"></div><div style="margin-bottom:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note 13&#58;  Related Party Transactions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation of Key Management Personnel</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of key executives of the Company and members of the Board of Directors.  </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and short-term benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">812,281</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763,951&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,405,350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,320,516&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359,024</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702,019&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,128,096</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869,090&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,171,305</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,465,970&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,533,446</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,189,606&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ex992-q32022mda.htm
<DESCRIPTION>EX-99.2 2022 THIRD QUARTER MD&A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i97d4db70582a44db9f25c6ac73673ced_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img alt="oncolyticslogotaglinebluea.jpg" src="oncolyticslogotaglinebluea.jpg" style="height:297px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">September&#160;30, 2022 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i97d4db70582a44db9f25c6ac73673ced_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">November&#160;3, 2022 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with the unaudited condensed interim consolidated financial statements of Oncolytics Biotech</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inc. as at and for the three and nine months ended September&#160;30, 2022 and 2021, and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) contained in our annual report for the year ended December&#160;31, 2021. The financial statements have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean Canadian dollars.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#8220;forward-looking statements&#8221;). Forward-looking statements, including&#58; our belief as to the potential and mode of action of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic, including our belief that by priming the immune system we can increase the proportion of patients who respond to immunotherapies and other cancer treatments in cancers where they have previously failed or experienced limited efficacy&#59; our expectation that, as our clinical development program advances, pelareorep's ability to enhance innate and adaptive immune responses within the tumor microenvironment will play an increasingly important role&#59; our expectations regarding increasing opportunities for expansion of our clinical program along with business development and partnering to address a broad range of cancers in combination with a variety of other therapies&#59; our belief that our adopted approach has the most promise for generating clinically impactful data and offers the most expeditious path to approval&#59; our expectations as to the purpose, design and outcomes of our current or pending clinical trials involving pelareorep and the potential opportunities that may result&#59; our planned 2022 development activity for pelareorep&#59; our planned 2022 manufacturing program&#59; our drug product supply estimates&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our business strategy, goals, focus and objectives for the development of pelareorep, including our immediate primary focus on advancing our program in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer (mBC) to a phase 3 licensure-enabling study, and our plans to explore gastrointestinal registration program opportunities through our GOBLET platform study&#59; the impact of the coronavirus infectious disease 2019 (COVID-19) pandemic and the global political conflict in Ukraine on our research and development activities, business operations and financial condition and results of operations, including our ongoing and planned clinical studies and manufacturing activities, our liquidity, and longer-term strategic development, and our ability to finance and execute our operations&#59; our ongoing collaboration with our investigators, partners, and vendors to minimize the effect of COVID-19 and the global political conflict in Ukraine and to ensure the safety of patients and employees, minimize the effect of supply chain challenges, and maintain the advancement of our clinical programs&#59; our expectation that the measures we are taking in response to COVID-19 and the global political conflict in Ukraine will allow us to adequately respond to any related challenges that may arise&#59; our belief as to the opportunities for the potential expansion of our clinical program along with business development and partnering to address a broad range of cancers in combination with a variety of partner therapies&#59; our plan to proactively manage all aspects of the development of our clinical trial program, our translational science program, our manufacturing process and pelareorep supply, and our intellectual property&#59; our plans respecting regulatory approval for pelareorep&#59; our expectations regarding enrollment under our various clinical trials&#59; our expectations respecting the delivery of additional clinical data and the timing thereof&#59; our anticipated milestones and catalysts&#59; our belief that we will have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months&#59; our plans respecting the maintenance of adequate cash reserves to support our planned activities&#59; the factors that will affect our anticipated cash usage&#59; our plans for funding our capital expenditure requirements&#59; our approach to credit rate, interest rate, foreign exchange and liquidity risk mitigation&#59; the effectiveness of our internal control systems&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. We may be impacted by business interruptions resulting from COVID-19 coronavirus and the global political conflict in Ukraine, including manufacturing supply chain, clinical trial and project development delays and disruptions, and market </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">volatility and uncertainty. It is unknown whether and how the Company may be affected if the COVID-19 pandemic and the global political conflict in Ukraine persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding among other things&#58; our ability to recruit and retain talented employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters, known as reovirus. Pelareorep has demonstrated the ability to create a more permissive tumor microenvironment (TME) and conditions the tumor for multiple treatment combinations, including checkpoint inhibitors and potentially other immuno-oncology drugs, like CAR T therapies, bispecific antibodies, and CDK4&#47;6 and PARP inhibitors. Pelareorep creates a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1&#47;PD-L1. By priming the immune system, we believe we can increase the proportion of patients who respond to immunotherapies and other cancer treatments in cancers where they have previously failed or experienced limited efficacy. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expansion of our clinical program along with business development and partnering to address a broad range of cancers in combination with a variety of other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to approval. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our program in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer (mBC) to a phase 3 licensure-enabling study. In addition, we are exploring gastrointestinal registration program opportunities through our GOBLET platform study.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i97d4db70582a44db9f25c6ac73673ced_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Quarter 2022 Pelareorep Development Update</font></div><div><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breast cancer program </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-development Agreement with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a human anti-PD-L1 antibody, for the treatment of HR+&#47;HER2- mBC. This phase 2 clinical trial is jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1, is a randomised open-label study that enrolled 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab. PrECOG LLC, a leading cancer research network, is managing the BRACELET-1 study. We completed patient enrollment in the second quarter of 2022.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study is examining the expression of immune-related biomarkers to identify changes in T cell population between pretreatment and on-therapy biopsies and seeks to confirm our previously identified biomarker. It is designed to assess efficacy in terms of overall response rate at week 16 per RECIST 1.1. The safety of the combination is also being evaluated.&#160;The results of this study may provide an opportunity to add an arm to our proposed registration study that includes a checkpoint inhibitor in addition to the chemotherapy-pelareorep combination. Furthermore, the results of the BRACELET-1 study may provide important confirmatory data in the same patient population as our IND.213 study, for which we presented a statistically significant near doubling of overall survival with pelareorep treatment in HR+&#47;HER2- mBC. These endpoints, including the biomarker data, are expected to further de-risk our contemplated registration study, permitting for a smaller study with a higher likelihood of clinical success.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the third quarter of 2022, we continued re-treating patients still on-study, monitored those patients who came off treatment due to progression, and assisted with follow-up activities. These activities included analyzing data on the study's primary endpoint on week 16 overall response rate and secondary endpoints of progression free survival and overall survival.     </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Triple-negative breast cancer study combining pelareorep and retifanlimab&#58; IRENE study </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, we continued patient enrollment activities in our investigator-sponsored trial (IST) managed by Rutgers Cancer Institute of New Jersey. This single-arm, open-label, phase 2 trial, known as IRENE, is investigating the use of pelareorep in combination with Incyte Corporation's anti-PD-1 checkpoint inhibitor, retifanlimab, in patients with metastatic triple-negative breast cancer (TNBC). This study plans to enroll 25 patients. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRENE study represents an expansion of our lead breast cancer program into a new disease subtype (TNBC). In addition to investigating the safety and efficacy of pelareorep-anti-PD-1 combination treatment in TNBC patients, the study is also evaluating changes in PD-L1 expression and correlations between treatment outcomes and peripheral T cell clonality, a previously identified biomarker of pelareorep response that may enable the success of future pivotal studies by facilitating the patient selection process. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Gastrointestinal cancer program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GOBLET platform study is a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The study is investigating the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq&#174;), in patients with metastatic pancreatic, metastatic colorectal and advanced anal cancers. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are safety and objective response rate at week 16.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2022, the pancreatic cancer cohort met the efficacy expansion criteria for Stage 1 of the trial. Per the study's Simon two-stage design, any cohort meeting a pre-specified efficacy threshold in Stage 1 (defined as achieving a minimum number of objective radiologic responses by week 16) may be expanded to enroll additional patients in an optional Stage 2 study expansion. The data from the phase 1b portion of this cohort showed a strong efficacy signal as evidenced by all patients achieving a partial response (n &#61; 3).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential blood-based biomarkers (T cell clonality and CEACAM6). Approximately 55 patients are planned for enrollment across four separate cohorts&#58; pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line advanced&#47;metastatic </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pancreatic cancer patients, pelareorep in combination with atezolizumab in 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line metastatic colorectal cancer patients that are diagnosed as MSI-high (microsatellite instability), pelareorep in combination with atezolizumab and TAS-102 in 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line metastatic colorectal cancer patients, and pelareorep in combination with atezolizumab in 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line advanced and unresectable anal cancer patients. We received clearance from the Paul Ehrlich Institute (PEI&#59; Germany's medical regulatory body) for full enrollment of the 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line metastatic pancreatic cancer and 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line metastatic colorectal cancer cohorts in the first and second quarters of 2022, respectively. As the trial's anal cancer and 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-line metastatic colorectal cancer cohorts do not include safety run-ins, all of the trial&#8217;s four cohorts have been cleared for full enrollment.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, we continued patient screening, enrollment, and treatment activities. In addition, we also continued patient sample analysis.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the third quarter of 2022, we continued distribution and storage activities with the product supply. While we currently have sufficient drug product supply to support our clinical development program, we continued our activities to maintain our clinical and commercial production capabilities. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of our submission to regulators, including the FDA, for product approval.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_22"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the third quarter of 2022, we had been issued over 243 patents including 24 U.S. and 11 Canadian patents, as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus product used in our clinical trial program that extends to the end of 2031.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. at-the-market (ATM) equity distribution </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2022, we sold 839,075 common shares for gross proceeds of US$1,024,531 at an average price of US$1.22. We received, net of commissions of US$30,736, proceeds of US$993,795. In total, we incurred share issue costs (including commissions) of $78,825.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended the third quarter of 2022 with cash and cash equivalents totaling $32,362,063 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Global Business Conditions</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2022, a variety of external factors, including the ongoing coronavirus infectious disease 2019 (COVID-19) pandemic and the global political conflict in Ukraine, have touched elements of our business operations. COVID-19, including its variants, has created challenges affecting our clinical trial activities, including delayed patient enrollment related to our BRACELET-1 study and contributed to the disruption of our manufacturing supply chain, while the conflict in Ukraine has increased market volatility and uncertainty. Some challenges included, among other things, patients choosing to delay treatments, clinical sites suspending study activity temporarily, vendor and collaborator staff shortages, and raw material and components delays. While these challenges have largely impacted the timing of certain activities, we believe the impact on our overall business to date has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, these events have caused and may continue to cause significant fluctuations in stock markets, global economic activity, including inflation and rising interest rates, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events might prolong and&#47;or cause significant disruptions to our business and materially impact our results of operations, including our ongoing and planned clinical studies and manufacturing activities, will depend on future developments. These future developments are highly uncertain, cannot be predicted, and could negatively impact our business.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor these events and their impact on our industry and business. We are collaborating with our investigators, partners, and vendors to minimize its effect and ensure the safety of patients and employees, minimize the effect of supply chain challenges, and maintain the advancement of our clinical programs. We expect these measures will allow us to </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adequately respond to future challenges that may arise. Moving forward, we plan to remain in contact with relevant stakeholders and keep the market apprised of any new information that may materially impact clinical timelines.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pelareorep Development for the Remainder of 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our planned 2022 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. Our remaining primary 2022 clinical objectives will focus on GOBLET enrollment and the assessment of our BRACELET and GOBLET clinical data to help form the nature of our registration strategy, our path to approval and other possible clinical development opportunities. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 manufacturing program includes assessing a process development plan investigating the application of single-use equipment to our drug substance production process. We also expect to fill product and perform the associated analytical testing, carry out process development activities as well as labeling, packaging, and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These activities are consistent with our planned process validation. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.    </font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_40"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Comparison of the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended September&#160;30, 2022 was $4,407,183 compared to $4,872,142 for the three months ended September&#160;30, 2021. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $399,791 from $3,278,705 for the three months ended September&#160;30, 2021 to $3,678,496 for the three months ended September&#160;30, 2022. The following table summarizes our R&#38;D expenses for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,363,948</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798,570&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,378&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">650,584</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,994&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,590&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">59,681</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,324&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,643)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">109,941</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,831&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(197,890)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,187,751</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020,860&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,891&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">273,700</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,621&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,921)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,891</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,505&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,386&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,678,496</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278,705&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,791&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses in the third quarter of 2022 was primarily due to the following&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses as a result of an increase in consultant support for our data management activities as well as a net increase in our clinical study costs due to higher GOBLET patient enrollment and sample analysis activities and lower BRACELET-1 patient costs as the study enters into the re-treatment and follow-up phase upon achieving full enrollment at the end of the second quarter of 2022&#59;  </font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased manufacturing and related process development expenses associated with higher production process and analytical activities, partly offset by lower routine testing activities as we focus on ensuring our active drug substance and finished drug product meet the regulatory specifications and standards as we advance our clinical program to licensure-enabling studies&#59; and  </font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses as a result of higher payroll costs.</font></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation as a result of the impact of the vesting of options granted in prior periods&#59; and </font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as our bispecific antibodies and CAR T studies ongoing throughout the third quarter of 2021 were largely completed by the end of the first quarter of 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $494,899 from $2,876,312 for the three months ended September&#160;30, 2021 to $2,381,413 for the three months ended September&#160;30, 2022. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees, and transfer agent and other fees relating to our Canadian and U.S. stock listings. Office expenses include compensation costs (excluding share-based compensation), rent related to short-term leases, and other office-related costs. The following table summarizes our G&#38;A expenses for the three months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,370,501</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700,773&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,272)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">686,870</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595,717&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,153&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">226,224</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,299&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,075)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,989</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,900&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,829</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,434&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,395&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,381,413</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,876,312&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(494,899)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses in the third quarter of 2022 was primarily due to the following&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased public company related expenses as a result of lower investor relations activities, partly offset by increased travel expenses with the easing of COVID-19-related restrictions and higher board of directors advisory costs&#59; and </font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation as a result of the impact of the vesting of options granted in prior periods.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Gain</font></div><div style="margin-top:10pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange gain was $1,525,514 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> compared to a gain of $1,212,070 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarter of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The foreign exchange gain incurred in the third quarters of 2022 and 2021 was primarily due to unrealized translation gains on U.S. dollar-denominated cash balances.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i97d4db70582a44db9f25c6ac73673ced_43"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Comparison of the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the nine months ended September&#160;30, 2022 was $16,280,513 compared to $18,553,023 for the nine months ended September&#160;30, 2021.    </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#8220;R&#38;D&#8221;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $1,349,564 from $9,240,900 for the nine months ended September&#160;30, 2021 to $10,590,464 for the nine months ended September&#160;30, 2022. The following table summarizes our R&#38;D expenses for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,674,955</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,576,886&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098,069&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing and related process development expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,670,765</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393,715&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">415,834</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524,763&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,929)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">250,204</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,515&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,311)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,592,412</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,119&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,293&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">910,973</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470,569&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559,596)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">75,321</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,998&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,323&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,590,464</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,240,900&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,564&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses as a result of a net increase in our clinical study costs due to higher GOBLET set-up, patient enrollment and sample analysis costs and lower AWARE-1 patient activities as study closure began in 2022, as well as an increase in our data management consultant costs&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses as a result of higher payroll costs&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased manufacturing and related process development expenses associated with higher production process and analytical activities, partly offset by lower routine testing activities as we focus on ensuring our active drug substance and finished drug product meet the regulatory specifications and standards as we advance our clinical program to licensure-enabling studies.</font></div><div style="margin-top:5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation as a result of a lower number of options granted in 2022 and the impact of the vesting of options granted in prior periods&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as our bispecific antibodies and CAR T studies ongoing throughout 2021 were largely completed by the end of the first quarter of 2022.     </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses decreased by $1,713,529 from $9,539,188 for the nine months ended September&#160;30, 2021 to $7,825,659 for the nine months ended September&#160;30, 2022. The following table summarizes our G&#38;A expenses for the nine months ended September&#160;30, 2022 and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,787,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,066,646&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279,646)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,027,627</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890,783&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,844&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">718,043</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,226,669&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(508,626)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,588</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,391)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">222,401</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,111&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,710)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,825,659</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,539,188&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,713,529)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 was primarily due to the following&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased public company related expenses as a result of lower investor relations activities, partly offset by increased travel expenses with the easing of COVID-19-related restrictions and higher board of directors advisory costs&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation as a result of a lower number of options granted in 2022 and the impact of the vesting of options and share awards granted in prior periods. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Gain</font></div><div style="margin-top:10pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange gain for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was $1,939,468 compared to a gain of $190,164 for the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2021</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foreign exchange gain in the nine months ended September&#160;30, 2022 and 2021 was primarily due to unrealized translation gains on U.S. dollar-denominated cash balances. The change in foreign exchange gain reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods.   </font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share data)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&#38;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,779&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,751&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,872&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,246&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,435&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,239</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,446</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,309&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,346&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,689</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,483</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,799&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,220&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share are share-based compensation of $499,924, $490,111, $638,981, $1,128,663, $1,006,920, $1,032,242, $658,076, and $1,704,453, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share are foreign exchange (gain) loss of $(1,525,514), $(888,074), $474,120, $325,800, $(1,212,070), 631,352, $390,554, and $1,052,531, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share were annual short-term incentive awards. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 3,662,653 common shares for net cash proceeds of $6.6 million in 2022 (2021 - 8,876,809 common shares for net cash proceeds of $33.4 million).</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="padding-left:36pt"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_52"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_61"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we are a clinical-stage biopharmaceutical company, we have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and through the exercise of warrants and stock options. For the nine months ended September&#160;30, 2022, we were able to raise funds through our U.S. ATM. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. On June 16, 2022, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150 million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries, and also may sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be affected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our US$65 million ATM equity offering sales agreement in June 2022 (see Note 5 of our condensed interim consolidated financial statements). We will use this equity arrangement to assist us in achieving our capital objective. This arrangement provides us with the opportunity to raise capital and better manage our cash resources.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2022 and December&#160;31, 2021, we had cash and cash equivalents and working capital ratios as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,362,063</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,262,044&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital ratio</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.69&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define working capital ratio as current assets divided by current liabilities, as presented on our unaudited condensed interim consolidated statement of financial position. The change in our cash and cash equivalents between September&#160;30, 2022 and December&#160;31, 2021 reflected the cash usage from our operating activities of $17.4 million, the cash provided by our financing activities of $6.3&#160;million, and the impact of foreign exchange on cash and cash equivalents of $2.2 million for the nine months ended September&#160;30, 2022. We do not have any debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments and contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated&#58;</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(17,416,436)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,098,335)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,318,101)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,740)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,236)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,496&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,334,841</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,067,387&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,732,546)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,237,354</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,979&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,899,981)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,867,795&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,767,776)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in operating activities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities was $17,416,436 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 compared to $16,098,335 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2021. The change reflected higher net operating activities and non-cash working capital changes during the periods. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in investing activities </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $55,740 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 compared to $211,236 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2021. The change was primarily related to leasehold improvements and furnishing our Calgary headquarters in 2021. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash provided by financing activities</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $6,334,841 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2022 compared to $33,067,387 for the nine</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September&#160;30, 2021. The change was primarily due to our U.S. ATM activities. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2022, we sold 3,613,760 common shares for gross proceeds of US$5,643,235 at an average price of US$1.56. During the nine months ended September 30, 2021, we sold 8,401,029 common shares for gross proceeds of US$27,158,080 at an average price of US$3.23. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to maintain adequate cash reserves to support our planned activities which include our clinical trial program, product manufacturing, administrative costs, and our intellectual property expansion and protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital. Additional activities continue to be subject to adequate resources, and we believe we will have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months. Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2022.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_46"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2022, we were committed to payments totaling approximately $16.8 million for activities mainly related to our clinical trial, manufacturing, and translational science programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with initial lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees or leases not yet commenced to which we are committed. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at September&#160;30, 2022 was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340,272&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,244&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,516&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_591"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at September&#160;30, 2022, we had not entered into any off-balance sheet arrangements.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_597"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2022, we did not enter into any related party transactions other than compensation paid to Key Management Personnel disclosed in Note 13 of our condensed interim consolidated financial statements. </font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_603"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our condensed interim consolidated financial statements, we use IFRS as issued by the International Accounting Standards Board. IFRS requires that we make certain estimates, judgments and assumptions that we believe are reasonable based on the information available in applying our accounting policies. Actual results could differ from those estimates.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies and estimates are described in our audited consolidated financial statements for the year ended December&#160;31, 2021 and available on SEDAR at www.sedar.com and contained in our annual report on Form 20-F filed on EDGAR at www.sec.gov&#47;edgar.shtml. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes to our critical accounting policies in the three and nine months ended September&#160;30, 2022.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i97d4db70582a44db9f25c6ac73673ced_64"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents,&#160;other receivables, accounts payable and accrued liabilities, and warrant derivative. As at September&#160;30, 2022, the carrying amount of our cash and cash equivalents,&#160;other receivables, and accounts payable and accrued liabilities approximated their fair value. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and therefore do not trade on an active market. As at September&#160;30, 2022, the fair value of our warrant derivative was $50,030 (December&#160;31, 2021 - $56,017). We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on U.S. Department of Treasury benchmark treasury yield rates with an approximate equivalent remaining term in effect at the time of valuation and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &#160;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;We are exposed to credit risk on our cash and cash equivalents and other receivables from Pfizer in connection with the BRACELET-1</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study (see Note 8 of our condensed interim consolidated financial statements) in the event of non-performance by counterparties, but we do not anticipate such non-performance.&#160;Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and other receivables.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We are exposed to interest rate risk through our cash and cash equivalents.&#160;We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. We are primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities are denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss in 2022 by approximately $188,000.&#160;</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies at September&#160;30, 2022 are as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br>U.S. dollars </font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,377,467&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,345,402)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705,472)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,032,065&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(705,472)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk through the management of our capital structure as outlined in Note 9 of our condensed interim consolidated financial statements. Accounts payable and accrued liabilities are all due within the current operating period.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_67"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 59,028,688 common shares outstanding at November&#160;3, 2022. If all of our options, restricted share units and performance share units (5,295,785), and common share purchase warrants with a US$0.90 exercise price (64,035), were exercised or were to vest, we would have 64,388,508 common shares outstanding.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2021 annual report on Form 20-F is available on www.sedar.com and www.sec.gov&#47;edgar.shtml.</font></div><div style="text-align:justify"><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_70"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures (&#8220;DC&#38;P&#8221;) are designed to provide reasonable assurance that information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in the securities legislation and include controls and procedures designed to ensure that information required to be disclosed by the Company in its reports filed or submitted under securities legislation is accumulated and communicated to the Company&#8217;s management, including its certifying officers, as appropriate to allow timely decisions regarding required disclosure. There were no changes in our DC&#38;P during the three and nine months ended September&#160;30, 2022 that materially affected, or are reasonably likely to materially affect, our DC&#38;P. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Internal Controls over Financial Reporting</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chief Executive Officer (&#34;CEO&#34;) and Chief Financial Officer (&#34;CFO&#34;) are responsible for designing internal controls over financial reporting (&#8220;ICFR&#8221;) or causing them to be designed under their supervision in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS. The CEO and CFO have designed, or caused to be designed under their supervision, ICFR to provide reasonable assurance that&#58; (i) material information relating to the Company is made known to the Company's CEO and CFO by others&#59; and (ii) information required to be disclosed by the Company in its reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time period specified in securities legislation. The Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) 2013 framework provides the basis for management&#8217;s design of internal controls over financial reporting. There were no changes in our ICFR during the three and nine months ended September&#160;30, 2022 that materially affected or are reasonably likely to materially affect, our ICFR. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the CEO and CFO, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </font></div><div><font><br></font></div><div id="i97d4db70582a44db9f25c6ac73673ced_612"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks and Uncertainties</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely upon our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the &#34;Risk Factors&#34; section of our most recent Form 20-F and our other public filings available on www.sedar.com and www.sec.gov&#47;edgar.shtml.   </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ex993-q32022certificationx.htm
<DESCRIPTION>EX-99.3 Q3 2022 CERTIFICATION CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib951596d6d084903a8f1d4a0e2911f4a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;padding-left:27.75pt">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended September&#160;30, 2022.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2022 and ended on September&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;November&#160;7, 2022&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Matthew Coffey</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Matthew Coffey, PhD, MBA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">President and CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ex994-q32022certificationx.htm
<DESCRIPTION>EX-99.4 Q3 2022 CERTIFICATION CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id7ac3aac2f1041609c751d3fa9f360d1_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM&#160;52&#8209;109F2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">CERTIFICATION OF INTERIM FILINGS <br>FULL CERTIFICATE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Review&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  I have reviewed the interim financial report and interim MD&#38;A (together, the &#8220;interim filings&#8221;) of Oncolytics Biotech Inc. (the &#8220;issuer&#8221;) for the interim period ended September&#160;30, 2022.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">No misrepresentations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Fair presentation&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Responsibility&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&#38;P) and internal control over financial reporting (ICFR), as those terms are defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">National Instrument&#160;52&#8209;109 Certification of Disclosure in Issuers&#8217; Annual and Interim Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, for the issuer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  Subject to the limitations, if any, described in paragraphs&#160;5.2 and 5.3, the issuer&#8217;s other certifying officer(s) and I have, as at the end of the period covered by the interim filings&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed DC&#38;P, or caused it to be designed under our supervision, to provide reasonable assurance that&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared&#59; and</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer&#8217;s GAAP.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Control framework&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The control framework the issuer&#8217;s other certifying officer and I used to design the issuer&#8217;s ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ICFR &#8209; material weakness relating to design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Limitation on scope of design&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  N&#47;A.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Reporting changes in ICFR&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  The issuer has disclosed in its interim MD&#38;A any change in the issuer&#8217;s ICFR that occurred during the period beginning on January 1, 2022 and ended on September&#160;30, 2022 that has materially affected, or is reasonably likely to materially affect, the issuer&#8217;s ICFR.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Date&#58; &#160;&#160;&#160;&#160;November&#160;7, 2022&#160;&#160;&#160;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Kirk Look</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kirk Look, CA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CFO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>oncolyticslogotaglinebluea.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M$0,1 #\ S^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                   -0  8WD
M F  #(     ,-@  ;R   U  !D
M
M
M
M
M
M
M
M
M
M
M                                                '57(=>< J I*
M]3KS*8X_]K_]@K;CF0H R"KSH<=9["F<;@%3G4XYE*?,AQSH8T7@-"KS*<<R
ME+K/8.=?0AD%7=3@I\R^KYAS+ZOF *@*?,OJ.=W>H [@Z;N]1QNOJ *ASN4N
M9?5\PYE]7S %7F4YYE*/,OJ'6>P K<RG/.I1YSGG0QIZC.A6ZSV'/.A1W0Y,
MF"MS(<[H4  2 4-SE'J8!6!3ZSV'9'H9!V!QN<@
M
M
M
M
M
M
M
M
M
M
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MN=T> 50=4>AV,@
M
M
M
M
M
M
M
M
M
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M>=0"9UGM'/[2)UGL.>= "8CD]2?$<[I[4(B*=N90"5OZE_"<HJ^Q2-SJ<H\
ME<WK11S(44D]ISS>Q/B )&YSS>M$(^_JW.R*OP@%?WOP'*;_  E#G.Z* 5.?
MUH=T4I<_QCL^#\ !6&Y33?X3GG0 K(\[HY"B!H"0"BCE0[H\ [@
M
M
M
M
M
M
M
M
M
M
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MM\"G;F7X0"O\'9[#GF5.]"DCD4[(X JHY%.Q2W1?8<]J %5%*B/(Z/13N 2
M4$4J(\P#N #(
M
M
M
M
M
M
M
M
M
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MVQ41Z%%'(<@$@%%'%5%W, Y !D
M
M
M
M
M
M
M
M
M
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MH"L#JCMSL-0  9
M
M
M
M
M
M
M
M
M
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M'='>CT@%;=4]J'=%**+\AV3V?( 52HU_K**..QAK4$@%%KMBJBC4'( ,@
M
M
M
M
M
M
M
M
M
M                                             '"KL%78HJNYA?U
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M[<J(OH7N!DK'*+L4>[N[4*B*#!71VYV(^Y6:[<P#L #.H
M
M
M
M
M
M
M
M
M
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M6NV*R+\@!(1=COMZ4(Z+M\'H*J* 5D4Y*7?VIW^H[H[< K-?ZRH1RHUWH,:
MJ  )@  R
M
M
M
M
M
M
M
M
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M9(:_UEL:\DM?\@!<FO\ 656N(#'_ "$AKOD )S7?(5$7;VI^ AM=Z4*['_H
M)*+Z4._?\)&1>WL^0JHNX!6:[T+WG<I)LO9W'=%]"@%9KO65".=VN]!AKP!5
M  3  !D
M
M
M
M
M
M
M
M
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M1%W *Z.]"G8I(N_9\BG9J^A0"LUWH*I'*C7&'^K_ +T!4 !G4
M
M
M
M
M
M
M
M
M
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MX2/[?5WH5$4 KM=Z%.Q2[_A3YSNUWR@%=KCN1T4K-=N8?B#L #(
M
M
M
M
M
M
M
M
M
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MP3=9V<Y7*YSE5SG.<]SG*KG.<Y5<YSG*JN<YSE5SG.57.5555W4X ):2T(=
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MB@$A%W.2@U=BN?/+V   ^@
M
M
M
M
M
M
M
M
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MN#!(!T8[<[GRO   'T
M
M
M
M
M
M
M
M
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MJ+Z4^, D]_PG=J_*444[KZP"JBE=%(Z*=VJ8!6 !D
M
M
M
M
M
M
M
M
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M_NC%<(1T2[VZ==).D>3M3*EDY+T^#55%ZPHKUX5P_7*7.<M6]."0 &^-"
M "YX3"7<I=IXW&U+-_(9"U!2HT:<+[%N[<LR-AKU:U>-KI)IYI7MCCC8U7.<
MNR(NZGS*22;;2T6NKY)>OP'%M)<6VDES;;[DEQ;?<N]EJ5R)W^/"]GP]AD@>
M2\\ACE=<+C=>\8J=S!Z,D9%=Q&D9%DIYO5$+VI)7LY/9S+.'PLK526.%6QY'
M(Q*U[?<M5[9)_03R57D/\?H?W#Q!XOU:F8U@YL-G!Z1D9'9Q.EMVH]+63YN>
M/*9[=4;'&B>X,8UKE;[KLRI)4R3$;V[KWD&=->LY^7B[-GXQLRX_D<<=_P!7
M;?H^2L=@>@G52O(S-JPU?"56%)<%IQ4\GBT]>:HY:??6]95K^7T9HK$:>Q='
M"8'%T,+AL96BJ8[%8RK#2H4JL+$9'#7K0-9%&QK6HG8W=R^^<JO57']8UGR'
M9K/7\A*;'M\)!LI-MMMMMMMMZMM\6VWS;[V3]&*222222226B27!))<DNY'1
MD?Q(26Q^/'Z?85(XE]7XO'PDUD7LW7YOS&#)19#X\=Q+9%Z.Y"JR(ELB\>L
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MU#NUVX!78IW*"*5D4PP<@ R
M
M
M
M
M
M
M
M
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M2QWYP"0BG=?7Z"@U?1\A6;ZO6 5CNQWH*+/4=P"0#AJ[H<F$  #(
M
M
M
M
M
M
M
M
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M^ K(I&8XK)V+[% *^_I]7>5$4I-7Y#LWL78 K-=M\!6(Y6:[<^7X^ .P /H
M
M
M
M
M
M
M
M
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MH 2 =6=QV/E/N  !]
M
M
M
M
M
M
M
M
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M5OJ^0ZJW?X?45]O5^<Z*FX!%<PHJWUDQ?4ORG1S/T@$![",YGK+BYNQ0<WY
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M6>-_CVEPC> 7:-WR>/'QDQB^@MD3_036* 7%CB2B^D@L=\Y*8OH )K5W^/\
M"56K\W81F*5D7M3V]_P@$A.U/@*C5W0I-78[-7T %9B]I6(Y7:NZ&&#D &0
M
M
M
M
M
M
M
M
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MK\AV1IV !RB;G9K=RHB&-0=4:=P!I_WX   R
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M!6.[%*+5]'J.^X!(!PBG(0
M
M
M
M
M
M
M
M
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M8[(@!P548<HW8[&.8  ,H
M            '56[E)4V*YPJ;F 4"GW=_<5G-V.ID%%6_(4E;Z4*W<OL4X5/
M5W $=4W3\*$=S=B6K?2GZ3HYO9[/P $!S?D(SV_(I/<W8H/;\@!;'L(KV>OQ
M^0N;V>@BO;ZP"T/9^DA2,\>HO$C=_'SD&1GYP"SR-_.098_'CU%XD807M_,
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M-R)8W;_"GCQ[?FUC/04Z5%W@QQ1TMKVMUSZ6.MI4U!4A]\^]IR_M7R]=L?\
MZ65E=5M5HMV\]FO$Q'LYE<FS$TKJBAFL;CLSB[4-[%Y:A3R>.NUWME@N4+]:
M.W3M0R,W;)%/7FCEC>U=G,<BIV%7^LSH[[BSNWKCI1F;UL4EPC:M.VAPY:MJ
MQ+1+2>D>$66PZJNDWN[9RHMEKDX6[3/5ZRG3I[Q9QXOR4ZY/GK7O2XRX_P!G
M"_<N$3BRQ.V5"YL<1N2@7J%Y<(W%FB=X]I<HG %VB=X]I/C=W%HC=X]I<8G
M%UC=Z/'L^0F1J6V-_9X^/U_"3F.[E +@QWI)35[2!&I+:O8 3.]/@_ 544H,
M=Z2JWTH 5]^U%]94*3>U-OC.[5[ "NQ3N46KVH5C'_\ @  ,@
M
M
M
M
M
M
M
M
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M/:5-@B;'9$!G4(FY61-@B;')@P  9
M                          !PJ%)R;%8& 1RGW? I6<W8Z*AD%)4]7<4E
M3;M^5"OW=B]QT5-@".YOR+W$=4]!+5-O@4I.: 0'M]!%>PN+FD9[?E0 MDC?
M3X\>A2%(STET>TBR-\>/;\P!:)&%OD87J1FWCQ\1;Y6=X!:)&[H6V1A>I&_G
M(,K "QR-+=*SO]GX/T%[E:6^5GS?@\=J %FD;\Y#>GS%S>WO0A/: 8>WG%O0
MBCQ63Q7&_ 4E94S=BMI_6Z01^\ARZ0N;@\S.C?W-M^"!V+GG<G(MJ&C$][9+
M$+),7,VE?2!X*8;B+HO4NAM00,GQ&IL59QMIKV\W4OD1)*MR+L566*%R.O>J
MRLVDAL5XI8E;(QKDUEW'G@KFN'&L]2:%U#'U>7TQE+&,MJC>5EAL:H^K<A[]
MX+U22"Y Y%5%BG8J.<G:MDNJOI)[IQ'AV/6[$2W-7QECOA!^OLG[V_"+J\2K
MO6]T8]RYD<ZJ.E&:WVFG!0RDM9</]=%=HO&:M;[M?R4 $K$0@  '"F<+YO-T
MO_U9<,+/#7*VVR9SAL^*MC62.VGGTC>?+)C%:B[=9'C+*6,<BM5W4UVU(G)'
M%U.^#V?>ODR^E3+P=XTZ-U;)-)'A+%Q=.ZKA8K=K&G,ZK*EMSVN5C7.QME:>
M9KHKV(MC&QL>Y(GR([C^G.P?W0V==7%:W5+MZ/%VUJ3W%\Y%RK\-91;Y':=
M.D3V;M.BV3THN:Q\A=RKMDDK'\U/=L??NQDES-E4QW87*%^_CQ^DL5.U'+''
M-#(R6&9C)8I8W(Z.6.1J/CDC<G8YCV.1S7)V.:Y%3L4ND3ORIX^8J.7,+S$X
MN<+O'X2S1J7&)_C\(!>(U+A$_N\?"6F-WCV$^)P!=XW$Z-?'L_1VEJC=V%PC
M=W>/@ +C&OS$UB_.6V->WQ\1-8O9\ !-8OH)"+W+\2D1J]RDIOJ *Z*=T[%V
M*+5["KOW+\0!5*Z+V% J,4P^0*@ ,I@
M
M
M
M
M
M
M
M
M               ,%)ZE-5[#LJE-Z^CUA Z>CX2D]?1ZRJ[U>HHKW_ @!T>[
MYNPB.7L*S_01GJ 4'J0I%\?,2)'=_P Q#D4 C2N\?-^<@2N)4KNWV%NE=^4
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M[?D .R)M\*_,=FIL<-3TG< Y1"LU-CAK=CL8Y@  R
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MO:J'< D X:O8<F$  #(
M
M
M
M
M
M
M
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M!V1#NB;_  ''L0J(FP!R5&-])U:G:5C#\/\ O0  &4
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M#N4F+VE4Q_W_ -_D  !D
M
M
M
M
M
M
M
M
MHO7M*Q051J#H_N*:]R)\9W?^,Z.7M *2]Z?*4'K\Y55>_P"0CO4 H/4AR+W^
M/82GKWD*10"+(I"E<2WK^ MTB]X!$E=X^ MSU)DSOR%OD=W@$*9WC\!;)7?D
M)TKBVR+^4 @SN^;\9;Y%]!*E7?Y57\?XD+?8F1B.>]=F,:KGKZFM3F<OMV1-
M]O9\0!AO^<P=(5<CJ[07#&E9<M;3.,NZKSE9C_V-^8SJQTL,V9FW[MC\34NS
M0N3_ -'G9&][5VQASZ[Z>_'MW$WC%Q UDD[;%/(ZANUL1(QW-$N&Q;UQN,=
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M0#NU/3\A5:GI.J)Z#NO?LG< =F)Z3N"HQ/2&P=VIL<@&$  #(
M
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MH+7DK)$:=:^Q/=>R;+(KWW"DLF'BX13C='7P[.3GPYRKB87B X0Y+2E2D
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MN1RNB@'(
M
M
M
M
M
M
M
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MX>PJH@!W;Z_45&=WPG1?0GJ*H!RB;E9#JQ#N8  !D
M                                                         HN3
M8K'5R;GSR^O_ +_K!05-REWI\!6*;NQ?8I]#4H/3T^HIO3YRNJ%+;L5/5W $
M-R=A$>GI)[T(KT +?(WO3Y"#(WO\>.TN4B$)[?'CY0"UR)V%NE;X]I=Y&^@M
MTS?'P=X!:I$+7*WO^4O4B?.6V5 "S2M[%^5"V2)\_C\9>96[%LE;M\7X/T %
MKD;\Q\]=*C@E5XD<.-<:$MJUK-5:9RV)@E<F[:V0EJODQ5[;945:&4CIW439
M=U@1/3L?14B$)_9\**?K1=*N<+(/2=<HSBUW2BU*+^II,_*^F-D)US6]"R$H
M3B^4HS3C)/VIM&I]R>+MT+-FA?KR5+]&S/2O5941):UVI*^O;K2(BJB206(Y
M(I$15V<QVRJB=L,]3?+.<!6Z"Z0FMH:T*0XW4\M;6..:QBMCVSL:R9!K7*FT
MDGU4CNRS.3]K).K-MTW7RR+I[*SXY6-1D1\VZJNU+PWXIN/MB]8OUIZ%%-K;
M/EB963BR\['NLJU\5"349?SHI27?H^*0 !L#7@  &<UYN9QQ=J+@=?TE9EY[
MG#W5F1Q\#5<KG_4+4#&Y_&O<Y>WWN2L9^I&S=6Q5JE9C51G*UN0-&[LW,'_S
M;SC5]1.+NH]'3R\M;6>EY)H&/?M&N3T_899BY6[^^L2U+-EC.Q?V-DO=L9OL
M:E3NL39_N?:V5HM(W..1'U]JMZ?_ ,O:%P^K/:?NK8V(V]9TQEC2]78R<:U^
MB[,NL*]_RESB=^(M$+N[Y/'SERB7N.(.]+S"I/C7N+7"[\7YRX1J 7:)Q<(E
M[/'P%JA7Y"XPKV[ %QC7N\>PFL4M\:]A.8O: 3&KV$QG;\A"9W$IB@%=O<5O
M^JI09ZBKZ/@4 K%5B]A11>PJQ^D J  )@
M                                                          '&
MX!R#CQX[SD  X.0
M     <*H!R#A#D  X&X!R
M
M
M
M                                 #C<* <@'"@'(.-SD
M                                 '" '(!P <@Z[J=@
M                                             "F_T%)3N[O*3^X
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MQ.Q/'>2V)\P!W3O3V%9J>GU%-O<5/1\(!W9Z_6=T"%1B>D J( #"  !D
M
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M89HG-?'(QRM<U45%V+L5R:TX-:-<&O LVGKQ7%/DT  8,@
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M7--/BFO D6,E))IIII--/5-/DTUP:?<P #Y/H
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M?:DU_P#SGIC^W&#<!]R[8_X"?Z>[_&/NM;;_  ]7]'I_PF<C^NQ>&WVI-?\
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M/5_1Z?\ "9R/Z[%X;?:DU_\ SGIC^W#]=B\-OM2:_P#YSTQ_;C!N ^Y=L?\
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MB^<FV^+[RR'0[:=V9LS#RKVI775;\VHJ*;WI+A%:)+1)<  #GCI@
M 6+4^<;C,;D,E(QTL>/HV[SXF;(^1E2O)8=&Q7>]1STC5K57L1515[$4OI_
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MT(=IAY%=R2UE&+TLA\NN6ED/YT5ZC^F !J#<@
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M$A$[?@3YP"HB=R%7T_ =&_@[3NP [E9J=A2;WE<P  #(
M
M     .%0H$@HO[S"!2=V*BG1R;*5']QT=W(ID$=4[T^,CO3M)3OS%!Z=GP $
M-Z=OPD*1.PN#R')Z0"W2)X\>U"!(G>7&1.SQX]!"E[P"U2IW_*6Z1._Q[2ZR
MH6Z1 "TRM+9*A>)D\? 6R7\8!9Y$[4^?X_R$&1.\N<R=_CO_ $$"0 _D]4Z=
M@R^-R&)M?O7*T;F-L=G-M!>K2U95Y55$54CE<J)NFZHB;IONFK$XG:(FTSJ?
M4>G+#%CGT_G\QA)HW;\S),7D+%)S5YO?;IU.W:F_K[C:L/3YC7;>6@X5_J4Z
M2O$J&.!8*>H+V.U?1[.5)TU'BJES)SM39$5%U F99S)NBK&N_ON8F3J=SM,K
M+QW_ !E,+4O738H/3Q;5S?L39!_7A@;V)A9*7&G(E2WH]=V^&]KZDI4)<=%J
MTN;/+H %A"MX   4SYO( <4?U0=';"XZ6=TUG2><SFGY&N[4@K-M>[\?"WWR
MJC4JW&/Y=FHBO54147=<!A3+6\V$XF*ZOQ:T9)(C6P6--ZJJ1*[MD=>BNX;)
M2-9MV) F-Q+7OW7=;,:;)MNL;]:F'VNR;)Z<<>VFW7OT<G2_7I[[Q]GJ9)_5
M#G=EMFNO7ADT7TZ<=-8Q5Z;XZ?Q32;3YZ+F99K'=WCQZ"YQ+^'?XBT,7L^#\
MWXE+E"OCY/R%7RV)=HE+I$O9\A:(E_$72%>X N<2_@+C$I:XE[BY1+W %SC[
MMR='^4ML2]GP+X_"7"->U/B_( 3F+V$MJ]J$)BDQ% )2=WP*5D4HM]/P?@*J
M=P!53O\ E,8;SJ/ZR^B/O@0_1-XR>/2GP)X^0QA_.H_K+Z(^^!#]$WCK.@OI
M? ^?7[,CC.L/T)M'Z-+]J)@:  MX4R   ,KGS?GRPWZCK6,X%<3LLJ:5R%I*
MW#[4.2G3JM-W[4OO=,7;4JIU6$NV)'+B99G]3C+4BT4=%3EJQ0YRVYIK7,14
M5%[47O3QV^.PSN/(#>6);K^A0X)\3,HOZN\33ZK1N>ORHKM88BE%_P!%V;#_
M -MJ/%UV;MZQ5?EJ$3IV.?:KV&N@?K+Z$:;^TL2OAQEEU17+O>1%+_YDEP^^
M<M]JP755T^U4-EYL^*TCAW3EJY<7ICSD^]<.Q;?%>]<U!/*;!QN<D'D_
M                    &*EYV#]:GA7]\J?^J><,%PSH_.P?K4\*_OE3_P!4
M\X8+A:+JL]$5?.W_ &DBIO6[Z:L^CX_[+  )&(Q!DS^:Q?7TUC][BU].XDQF
M#)G\UB^OIK'[W%KZ=Q)R'3ST1G?,_P!^!V75YZ;V=\]+[*9GT@ J,7.
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M\4Y*+X;VJ>EM>C.W/W1PJ<SL;*.V3?9V::^3)Q<HOAO0DTW"3C%RCH]W1IL
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MO6F#>=&/26S_ *=B?VBLY[I=Z)VG_P"GYO\ 9K369@ N84@
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M*^-;G')KCI&<8):N^*\FN6KT4XZ0G)J.Y%Z;WO2 ")29
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M .["J=6)V'8QW@  R
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M)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D %1BYP
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MJ==_UFO'O24ZZ6^E-H?3,G[61=[H=Z)V;]"QOLH@ '/'2
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MB]'IXI\T^36C7!EV<#.JR::LBF2G5="-D)+OC):KV-<FN:::?%  'E/6
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MFVL%Y6'EXT9*$LC&OHC)IM1=U4ZU)I<6DY:M+CHC3Q]OL';[#:\?WM'HX_\
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M5+RI/5)ZM<'RU  -*;T         '\!Q7_@MJ7^0,S]'63^_/X#BO_!;4O\
M(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_W23^,D_IN*15G_=)/XR3^FXI%Y"@
M,.2]B_4  #Z(M[]PF_BI/Z"FX X!?P$T5]R6G/H>F:?^]^X3?Q4G]!3< < O
MX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MZ(_N9A=I='3+RU&RY/G5#3WJCU.*>]8OPDG'5J$6  1Z22
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M2M_5-$UB=WQ?,A<84_)^(@QIW>/47&+N3VJ<F=B7")/'P%TB_$6V$ND2=GS
M$Z)"XQ=WR$"/\A<HT^=0";'W)X]"$YG?\I#C\>/B)T?X@"6SN)C4[2)&G<3&
M=X!73N^'8K(A1_ZOCTDAG> =D[_'P%0Z,]*^TJ(G: 5D.0#$?^(  ,@
M
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M/GJ]7&,-*@]8/32>ULIQKE)85$G&B')626J>1-=\I_ 3\R&BT4G/4 #O"/P
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MREST:U+,]'>A6S]F17N:A.WX61;I9?+Q\MKR$_BUJ$>_37B  <P=6
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M4G]!3< < OX":*^Y+3GT/3(1ZZ/O>SOEY7[..3YU&>?M/Y.)^O)/UH $"EA
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MA)#/3\!13O\ B_(54[E\=X".[.XJL[RFSN*K "J #"  !D
M
M          %)Y37N*KRF87) I+W(4'=Z%;?L^,IN]'PF01G]Q&D]!+D]/P_C
M(KP"#)Z2%)X^4GR>GQZ"#)W+\/XD_( 6^3O+;,G>7.7O+=.G?\?S %ND3O\
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MIIR@VFE-*3BW%Z:22DG%M:I--,[  _0^#KMV[F2MY!3RO\G"?-U^$O$;*_\
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M'[W%KZ=Q)C,&3/YK%]?36/WN+7T[B3D.GGHC.^9_OP.RZO/3>SOGI?93,^D
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MQBM%&,5HDDN"2X(  _,_4
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M&E%Q;36C3::?--<&G[&7/C)22DFFFDTUQ33XII^#0 !@^@
M :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB7NIO^'Y7T-_;TD,]=GH
M[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_=3KO^LUX]Z3P6\VQ^Q4TO\
M=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$  YXZ0
M                X5#Y%Z='1#P''+ACJ7ASJ!K61Y>KUN*R/+S387/5-YL1
MEZRIW2T[.W.W96S5I)X'M?'*]COKL'[8V1.FR%M<G"RN49PDN<91:<6O8T?A
MDXT+JYU6Q4Z[82KG"2U4H33C*+7@T]#3Z\8.%&<T'JO46BM34Y,?G]+9B[A,
MK5E8]BLM4I5CZZ+G1%DJ6XNKN4;+>:&W2L5[4#Y()HWN_.44S:?.9_)T)F,/
M7Z06EJ".RFGZ]3$\0X:[%22YI]KDKXO4,K(XG=;+A9'QT+MA[FNCQ4L#GJ^O
M0;U&$L6_Z*]((;2PZLF.BGIN70UXPNBEOQ^2]5.&O%PE'7CJ4KZ7='+-E9UN
M++5U_?*)M??*9-[CUY;RT<)^$XO3@  =&<T#ZMZ$G2YS_ WB9IGB1IY%FEPM
MML>6QBN5D6<T]:<R/-8:5=T:QURGS^XYW<S:F0CIVUCE2!8G_*1QL?AE8T+J
MYU614Z[(RA.+Y2C):2B_:GSYKFC]\;)LILKNJDX6U3C97-<XS@U*+7L:Y/@^
M3X&X*X1<5\%KG2^!UAIF['D<!J3%U,OBKD:MVFJ7(FRLYT:YR,FB5RPV(E<K
MH9XY(G^_8I^CF%/YLGY11:&1O='O55Q?<F2]UY[AQ;L2-2.O?CVFSFED5WOO
M\.B5^9Q";\C9:N5JJ[K+&/@7-8*?=)]@SV;F6XT]7%/?IG^$IDWN2]JT<9^$
MXR7):EU>B?2*O:F#3E0T4FMRZ"_B[HI;\?8]5.'C"47S8 !SYT@    .%4 *
MIB0><W^4+?A<%C^ .E[ZQ9'4T4&9X@35G[30:;CD<_&:><]OOHOJY>B9<O\
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MOG9+G5%KWN.DVM]Q[,AR 0J3N
M       >3GER=;+@NBMQ?E9*D4V1P-7!1>^:WK&YK+X['6HDYE17+)0GMIRM
M1SE3?9-MU36(IX\>/@-C?YR%DI*_19U,V/EVM:DTC5DYDW_8Y,LQ[N7U.WC;
MV]NR;]AKD$+(=4%6FSK9_'R[/]VJE?\ '^LJ[UU7Z[5HK^)A5O\ /NO?]TY
M!+!$(/TO@MPS?K76>C]&1O?&[5VJ].:726/]O F?S%+%/L(J-?R^YV6W3.>K
M'-C;&KW(K6J?FA]L>38FJ,Z0?!9UYO-7_NE:3;LJ.=_A#\I RFNS51?>W'5W
M(O<U4YG>]13R;0N==%]D?.A39..G%ZQA*2T7M1[-G51LR,>N6F[9?5"6KT6[
M.R,7Q7+@^?<;63"8>KCJ=3'T8(ZM*C6@ITZT+4;%7JU8FP5X(F)V-CBB8R-C
M>Y&M1$[BZ'5/2=BD;>O%\R^:6G!<$@ #!D
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M/XR;'Z/'I(4?X_RD^/T $QA(9W$=G<2H_0 5T[U^([^A?B_&4V]ZE7T?'^(
MJM[D*L?I*2=R%6/T@%0
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ME6'CTXM$=VJF"A%=[TYREISE.6LIOODV^\  \)L
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MVA],R?M9%WNAWHG9OT+&^RB  <\=(
M  ?SNK=*8[/8O)83,4Z^1Q.7HV\9D\?;B9/5NT+T$E:W4L0R(YDL-B"5\4D;
MFJUS'*BHNYJY/*D=!&]T>N+F:T5R6)-,W6_5W1&1L*^1;VFKDTC((7V';]=;
MQ,[)<9=<YRRND@CGDW2S&]^T]/'KRU/D[8ND#PFLP8JK&_B!HKW7GM$659^R
MSSK%$N6T^KT5KO<^?JU8H>5>9C;];'6%C>^NQ$[[J]Z4?N=F*%LFL7)<:[N/
M"$M?>[OYC;4W^#E)Z-Q2(YZRNB7[IX+E5%/+Q=;:-/.LCI[Y1K^.EK!<NTC!
M:I-LUF@*MBO)#))#-&^&:&1\,T,K59+#-$Y8Y896.1',DB>US)&.1'-<U6JB
M*A2+5%10  #^KT#KS+Z6SN(U+I^]+C,Y@<C4RV)OPK^R5;]&9L]>5$[GL1[$
M26)^\<T2OAD:Z-[D7::^3<Z;.*X_<)--<0**Q5\I/"_%ZKQ+'M<_#:IQO+!E
M:;D:B*V"P[J\GC7N:U9L7>I3*UCWOC9JGSW2\@KY13^XEQ7@TYJ&VL/#WB39
MHX/,R22N;6P>>?)[GP&H7HJ*QM9MB9,;E97=6D-&TEY\K8J$C)8XZQ^B_N_#
M=M4=<G%WK(:+RIU\[:O6VEOP7/?CNQ\]DE=5_2K]SLY4VRTQ,QQKLU>D:[==
M*K7X+5]G-\%N2WI/2"TV/P.$4Y*O%M@    >0'EI_*$Q\ >#^1MXFQ'^K[6+
MI=-Z*K<R*^K9L1*N2U#*S]LE; T%DL1KRJDV4DQE1W)'8EFA]NSMGVY5]6-3
M'>LNFH17=QYM^$8K64GW13;/!M3:56'CW9-\MVJF$K)OOT7**7?*3TC%=\FE
MWF+KYQKY1%_$CB/'PGTS?Y]#\-IW-RSZSVN@SVN7HZ.[,^1FZ34].UG)C:36
M.ZMV0FR\TB2HRDZ'&X*UFU-/++/8EEL6)Y9)Y[$\CI9IYYGNDFGFE>JOEFFD
M<Z261[G/>]SG.55556B7%V'LBK Q:<6I>35'1RTT<YOC.R7KG+5^I:17!(I-
MM_;5NT<N[,N\ZV;<8\U76N%=<?5"&BX<WK+FV  ;8TX/H_HC]%_47&7B)IGA
MSI>)RY+4-YL4UOJ7S08G%P?LN5S-MK.ZMCJ;9)EYW,;++U4'6,69')\W.<B(
MJKV(G?[#8$^;J>3<=POT#/Q4U72Y-<<2:=23'5[$*MGTYHQBNGH5&I(G/%>S
MLKVY3)KLS_!X\541B+5FDL<GTRZ20V9A67:IW3][QX/CO6M><U\6M>7+7@]%
M'@Y(Z_H1T8EM7.KHT:HKTMRIKANU)^:GS4K6NSCIQ6KFM5!Z>['1MZ/NG.%F
MA=,</M*5?<N"TMB:V+IH_E6Q:?$WFM9&]*UK$GR.3MNGOY"QRMZ^W8EDY6M<
MC4_<0"H]MLIRE.<G*<Y.4I2>KE*3U;;[VV]6RYM-4:X1KA%1A"*A",5I&,8I
M*,4NY)))+P  /S/T                              !BV^=9?6<X???%
M;_5_*F4D8MOG67UG.'WWQ6_U?RIUW0/TQ@?/?W)G$]8_H/:/S"^T@8(( +<K
MDBF<.0 !D^CV7\@%]E3P[_B=0_0UDV7)K1O(!?94\._XG4/T-9-ER5LZWO2=
M7T2O[6XM#U+>B[OIEGV5( !%1+X                           /X#BO_
M  6U+_(&9^CK)_?G\!Q7_@MJ7^0,S]'63]*?/C\J/ZT?G;YDODR_4S3YS_ND
MG\9)_3<4BK/^Z2?QDG]-Q2+R% 8<E[%^H  'T1;W[A-_%2?T%-P!P"_@)HK[
MDM.?0],T_P#>_<)OXJ3^@IN . 7\!-%?<EISZ'ID(]='WO9WR\K]G')\ZC//
MVG\G$_7DGZT "!2P@               /F7ID=(['<(^&&MN(N4>Q*^E\#;O
MP1/5K?=>2<U*^)H1\[FM?-?R<U6G#&JMZR69K$5.;<^FC$1\ZMZ4+Z>G.'W!
M_'V'L?GLE-K74K(Y.7K,;A&R4<#1G:W=)8+&5M6<D^.1&\EG"X^9B/5-X]_T
M7V1[NS\;&X[L[$[-/P4$YV?6X1:7K:.<Z6[:_<_9V5E\-ZNO2K7D[;&JZN'>
ME.46UX)F&-KG6V3U-F\QJ/-6'V\QG\G?S.4LR.<Y\]_)69;=J17/5SE19IGH
MU%<JHW9N_8?RP!<>$5%)))))))<$DEHDO4EP12.4FVY-MN3;;?%MOBVWWMOF
MP #Z, ]F/(E>3;3I!\4$EU!4DEX<:&=2RVL-TD;!EYY9'NQ6E^N;LB)E7UY9
M<@QKFR_4NO98Q6/GCD;XY8_'6+EFO3J0OL6[D\-6K7C3>2Q9LR-@KP1IZ7RR
MO9&Q%V17.3M0VDODJ.@[2X!<&M-Z-1D<FH;S?U1:SR#8T9)>U-E8H7VVJO(Q
MZP8RO'6Q%)C]W,J4(N;FD?(]T?=8O29[/PG"J6[DY.M=+7.$4EVMJ\'&+48/
MFISC)>:R1NK/HJMI9ZG;'>Q<32VY/S;)MOLJO7O23E-<4X0E&7G(]&*M2*"*
M.&"*.&&&-D4,,3&QQ111M1D<<<;$1D<<;$1K&-1&M:B(U$1-B0 58+=
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M8OBFB\G1W;5>T,*C+K:TM@G.*_B[5PLK??K"::]:TDN#3.0 :<W0
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M ! %5.Y"K'Z2DG<A5C](!4
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MZ>/2 3HN[Y"='Z/'H(,7=\A.C]'CT $IG>2/^KX])'9WDA/0 5V=YC"^=/\
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MM":U<=,6EZ<FU&RYKUZ.J/BDY+E([@ @DL(
M                    84OG6?2/=-G.&O"6G97JJ&.MZ]SU=O<LN0L6<'IU
MKW-5$7E91SLSH7[\J^Y9D:W=CW8A)Z=>69XTNUYTF^+682?KJ>/S\6EL6C9%
MDA90TICZN":L&_[6*U:IV\BYJ;)U]V=VR*Y3S%+@="]G+%V7AU::2=,;9^._
M<NUEK\ESW/9%%*NG&U'F;6SKM=8J^=-?'5*NA]C#3P4E#?T7#63?-L  Z@Y0
M'ZUP$X*YCB1K72N@M/L5^8U;G*&#INY%D;6]V3(VQ?E8W95KXVHEC(6>7WWN
M>K+R(YVR+^2F3IYKKT:&:EXM:JXC7:Z24>'> @IT'R1M>Q,_JIUF&%T?/VI+
M6Q>.R#^L8BNBZ^-%Y>N:JZ3I)M98.#DY7#6JIN"?)V2TA4O8[)13]1O>C.R/
M=^T,3#X[MUJ5C7-503LM>O<^SC+1^.G,SA.!7!K"<.]&Z8T+INNE7!Z3PF.P
M6-BV3G=!CZS(/=%AR=LMNV]K[=RP]5DLVIYIY7.ED>Y?U@X1#DIK99*<I3DW
M*4FY2D^+E*3U;;[VV]67@JJC",80BHPA%1C%+11C%:1BEW))))>  !\'V
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MLB[W0[T3LWZ%C?91  .>.D                                    ,
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M^^K&^?OB791]BJ4.'QG)][  .")#
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M5145%0JG%G<@
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M0
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M[.19'CWPNQBKF:==\_$?2]"!'.S%.!O-^J[%P1-YOJK2@1S,Y5:CTR-*.&[
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M3E*+?%_Q>XEZDN"  .(.]
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MLS\K):_@^.H1]4[Y\]/D537AY7+EI]+  KJ69
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M?7IK^]K+$OQJ5VT?]ZM:>O0ZGH3F^Y]K[.L_^ZJJ?JC>^PD_8HV/7U:HV:8
M*>EUP               :N7RS?V4_&[[KXOH'#&T:-7+Y9O[*?C=]U\7T#AB
M7NIO^'Y7T-_;TD,]=GH[%^F+[&T\R0 6**R@ 'S/D?,^1L9_-L?L5-+_ '4Z
M[_K->/>D\%O-L?L5-+_=3KO^LUX]Z2G72WTIM#Z9D_:R+O=#O1.S?H6-]E$
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M3D/:5\/>,66[CIKA9D<W/CSC0M&FN#LE'1ZURBO[38Y *[%F@
M                         8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5
MO]7\J==T#],8'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._
MXG4/T-9-ER:T;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2
M 142^                           #^ XK_P6U+_(&9^CK)_?G\!Q7_@M
MJ7^0,S]'63]*?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+
MR% 8<E[%^H  'T1;W[A-_%2?T%-P!P"_@)HK[DM.?0],T_\ >_<)OXJ3^@IN
M . 7\!-%?<EISZ'ID(]='WO9WR\K]G')\ZC//VG\G$_7DGZT "!2P@
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M-_6V7SQZ8U5PK@M(5PC"*\(PBHQ7U)(  _(_8
M                      'X]T@.!NGN)>C-1Z$U53;>P.IL79Q=^%4]^QD[
M%2.U7?\ MH;=.9([52=BMDAL11R,<CF[G["<;'W79*$HS@W&46I1E%Z.,HO5
M--<FFM4S\[:HSC*$XJ4)Q<91DM8RC):2BT^#33T:\#4Q=-WH>:HX%<2-0<.]
M4UY4DQME\V$RJL5*FH]/6'J_$YRA*F\<D=JORLN1,<Y]#(QW,?81EBK(Q/DT
MVA7E4_)DZ<Z2>A'8B>2'#:VP39KNB=4.B5_N"\K463&Y-D>TEG!Y5&I!<C:K
MI:<BQY&JR2:M[GL:U;C]P!U?POU9E=$:YPUG!ZBP\W5V:=AJ]7/"Y5]SY"A/
MLD=W&W6-66G=@5T4S-TW;(Q\;+5=".F->TZ%&;4<NJ*5]?+>2T7;5KOA+X27
MWN7DO@X.50.GO0FW9&0Y0C*>#;)^Y[=-=QO5]A8^Z<5YC?"R/%>4I1C^/  [
MLX(   '1T:+WHB^GM3?;X/5M[#N#&AC0^X>C1Y2?CIPADC30G$O4N/QS'(KM
M/9&XN?TR]%5.L1N SB7\=3DF1&LEM8V&C><UK$;:;R,Y<@?HY^=8:CJ-KU.*
MG#?'YAK6HV?-:,N/QEF1V^RR.PV4?:KM1J>^5D6157NW1O(BM1,1<'-[6Z([
M.S=7?B5.;_C(KL[/:YU[LI?SG)>HZC9'3/:F#HL;,M4%II58^UJ]BKM4XQ]L
M-U]VILK. OG /1>UT^&K)KW]1.3F3]XZ^QMO3D#5V;OS9Z1D^F&)S.Y6MES<
M4S]E<V'E153UWT?K[!:AIP9# 9G%9NA9B;/6NXC(5,C5G@?MR30V*DTL4D3M
MTY9&/5J[ILJ[H:=O8_1.&7%W5>BKB9#1^IL]I>ZDC95GP.6NXM9'L5'-6=E2
M:**RU%:U>2Q'*Q>5N[5V3:/-I=3E$M7B95E3^)?&-L?8I05<HKVJ;)*V7UVY
M,=%F8=5J^/CRE5+33OA-V1D]?"4%I[..X,W.37!\ /.+>DMHCJ8,GG,%Q"Q\
M:[/K:UPZRW',54YUCS&$LXC(-FY41L3[+[D$:^_=6DW<CO?GHS>=(\)]2+7I
M<2=*9_AQ?DV:^_4F35VF^;L:CEN4ZF/R]=)';N7K\)[GKL7W]QZ-<\C[:G5I
MM7&3E&F.3!:^5C2WY?HY*%KU_%A)>LDC9'6KL?+:C*Z6+-Z>3E0[./=_&Q<Z
MEHVEY4X^I-)F4&#\(X%=)WA]Q-QWU5T!K'3^K*2-:^1V&R->U/7:Y>5ONNFU
MR6Z:JY%1J68(E<J*C=]C]V0X2VJ<).$XRA*+T<91<9)^#32:?M1(=5T+(J<)
M1G"2UC*$E*+7BI)M->QG( /S/T
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M!(9W@)G=G<5&=Y285$7M *X ,+D  #(
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M-HT:N7RS?V4_&[[KXOH'#$O=3?\ #\KZ&_MZ2&>NST=B_3%]C:>9( +%%90
M#YGR/F?(V,_FV/V*FE_NIUW_ %FO'O2>"WFV/V*FE_NIUW_6:\>])3KI;Z4V
MA],R?M9%WNAWHG9OT+&^RB  <\=(
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M)LN2MG6]Z3J^B5_:W%H>I;T7=],L^RI  (J)?
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MVKLZ/_WF/+GIYED9K^N)L>P<(<E-R[@
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M)*4)1?)QDM4UZTSD 'Y'[
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MG#^,M,:]GP?E+E"IQ9W9=H5+I$O86B)?Q%TA4 N<2_@+C&O86N%>[XRY1+^
M N4:DZ/\Q;HU[O'L+A&O;X]7Y0";&O<3&+VD)G<2T7N )2=WP*5T792@GI\=
MQ510"JU>U4]JE0I[]J+X\(5 "0B@X:O8<@
M
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ME9%>;-\$HRB5(ZPN@\MDW]K2I2P;I>\R?%U3T;=%CYZI)NN3\Z"XMRC(_"0
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M?^J><,%PSH_.P?K4\*_OE3_U3SA@N%HNJST15\[?]I(J;UN^FK/H^/\ LL
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M.&C  ),(J!]2]!FI+8XT\)X86.DEDXA:4:QC>USG?5BJNR)Z^Q3Y:/OKR5>
M^JG22X(TEC61K^(VGK$C$5Z*L-&RMV==X_?MVAK/55141J(KG.:U'*FMVQ/=
MQ,F7Q<>]_DJD_P#@;#9%6_F8<.6]E8\?SKH+U_J-JL "E)?
M   &KE\LW]E/QN^Z^+Z!PQM&C5R^6;^RGXW?=?%] X8E[J;_ (?E?0W]O20S
MUV>CL7Z8OL;3S) !8HK*  ?,^1\SY&QG\VQ^Q4TO]U.N_P"LUX]Z3P6\VQ^Q
M4TO]U.N_ZS7CWI*==+?2FT/IF3]K(N]T.]$[-^A8WV40 #GCI
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M[NNC^^<R*W$UHZL;76"7@[=%9+\7LUS3.0 162\
M                  #%M\ZR^LYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3K
MN@?IC ^>_N3.)ZQ_0>T?F%]I P00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK
M)LN36C>0"^RIX=_Q.H?H:R;+DK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
M                          ?P'%?^"VI?Y S/T=9/[\_@.*_\%M2_R!F?
MHZR?I3Y\?E1_6C\[?,E\F7ZF:?.?]TD_C)/Z;BD59_W23^,D_IN*1>0H##DO
M8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_ +W[A-_%2?T%-P!P"_@)
MHK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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MIENL#.JR::\BB:LJM@IPFN3B_P!37*47QBTTTFF<@ \IZP
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M&+W>/856>KU$>-20U-E4 K>A/8I512BWTH5&+V %9BE0HM7M*Q@  &0
M
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M^OIK'[W%KZ=Q)R'3ST1G?,_WX'9=7GIO9WSTOLIF?2 "HQ<X
M   X4U-?E -!/TQQUXQ8-S.K;3XEZREKL5-E91R.=NY3'M7M=ORT+M9.;?W^
MW/LWFY6[9136T><,\+'::Z4>L[:,VAU;C-.ZHC>B.Y'R38R/$SHBJB)SL=B6
MK*C=TYGHY55SU)<ZGLO=S\BE_P ;C;R^559'3_=G-_40UUUXN]L_&N7\5E*+
MY<(VUS7M\Z,5HOKY</$< %C"L@.%4Y ,-&=!YJ;Q-;<X9\1M)R2IUV"UE7R<
M$/9NE/-8N'FE7L141UJG,Q-U7]IV;=J)E8&O^\U[XZ1Z?X[Y[15F9D4'$/1M
MME-CW;.LYO24KLS5KQ-7]LY<+/J*T_EW<C*:]BMW5NP!*I]96"Z-KY#TTC>J
M[X^M3@HR?Z2$UW\O$M_U6[05^Q<5:^5CNS'DM=='7-N"YM_>I5O3AIKP6F@
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MCMZ>Z<=2CZYT2U2Y?$LL?-+R3(7 !7,LT
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MVWKL8Z>O6Q'5=!L/M]L;.KX\,JNUZ:<L?W]II]S5?'U:Z<3.Q !3\NL
M          #5R^6;^RGXW?=?%] X8VC1JY?+-_93\;ONOB^@<,2]U-_P_*^A
MO[>DAGKL]'8OTQ?8VGF2 "Q164  ^9\CYGR-C/YMC]BII?[J==_UFO'O2>"W
MFV/V*FE_NIUW_6:\>])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
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M\M+RJV^Z-L?)?<I;DGYNAJMP4*\W6,8].Q'L:]$]7,U';?$B_F*Y;5,INF
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M-9-ER5LZWO2=7T2O[6XM#U+>B[OIEGV5( !%1+X
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MJR=<OE0DXO\ K1?3#R8W4U70\VVN%D?DSBI+EJN3  /.>@
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M3CU,])G"^S9=LO>[5*[&3?FVQ6];6O59!.Q)<$ZY-+6;,E0'"') !8\
M                                     CG1W>A47O4IO[@"F[O4HKZ?
MAW^4KN_$45[U^  BO[R*_P!/QDR1"*_O4 @2$*3T^/23WD*1/'Q?E +8].PM
MTB%UE3O+;*G> 6R1"US)X^8N\B=_RELE;^0 M,R=_P I;9$[53QZBZR)W_ 6
MV1/'CVH >9/E>^%_ZK>CGQ0QS6+)-2P3<_5C:U5>^UIVY6S-=C-NU'/DIHW?
ML3951WO55%UQC7;ING<J(J?&;7'7VDH<]A,U@IVQNAS.*R&+D25J/CY<A4EJ
MJY[7(Y%1G6\_<NRM143=$-5GK'3$V#S&7PEACX[&&RN1Q4\<G9(R7'6YJCVO
M3T.1T*HOM[2?NIO-UHS,=_Q=M=T5\[!PE]E'\I7/KPP-,C RDO/JMHD^'\5-
M3@O'E=/N[N9_.  FH@L   H66*Z-Z(JINUVRINBHNW8J*G:BHO:BIVHO:AM*
M.C5Q59KCA]HG6#9$D?J72V#R]AR*BI[MMX^!^09NB(B]7>6Q$JHB(JLW1$[D
MU;JIN9[OD!>,7ZI^CWB,7+,LMO16:R^FI6JY5ZJMUR9/'1INJJW_  .^QVW8
MF[U5J(BD0=<. YX>-D):]A?*#]4;X+5^S>J@O:T31U)[0W,[+QF]%D8\;(\O
M/QYM:<^+W;IO31\$^1[=Q+W?(3XW?@_%^4ML:D]B]R^/&Y78LP7:)W=[4+E$
MOY2T0K\RERB7Q\(!>(U+A$I:XE["?$H!=HU[O'CL+A&O;\/C\):XU["?&O=\
M7CY0"Y1J36.+?&I,8O8 3F+VE=%[OA(K5[E)*+W@$A%[2HG>ORE!J]A6W[E
M*A712@BE5BF&#N #(
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M=I6MVV*]<J]V:7A5)GNR " 2Q@
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MZ23]:::9>*FZ-D(V0DI0G&,X27%2C))QDO4TTUZ@ #\S]
M             ?C/2(XU8OAOH36&OLUVXS1^G,MJ"U$DC8I+3<92ELQTH7N:
M]$LWYHXZ51.K>KK,\3&L>YR-7]EW,5[SH+IE1Z<X?Z?X.8J[RYC7MEF9U!!!
M,K98=)X:RUT#+3&.W2'+9ED4<,<K4;8;C;CHU5:K]MWT<V2\[-Q\5)Z66+M&
MO@U1\JV7#EI!2T]>BYFAZ3[9CL_ R<N32=54NS3^%;+R:HZ=^]8XKV:OD8.^
MM]:Y+4N;S&I,S-[HR^H<KD<YE9^U$ER.6N37[LC4555K'6)Y.K9NO(SE8G8T
M_F0"Y<(**2BM$DDDN"22T27J2X(H]*3;<I-N4FVV^+;;U;?K;?$  ^C -@#Y
ML!P0?I[@1E]63Q<EC7FL+]V%SX^61<;A8(</55KU_;5Y)H+4T:)ML]TF_:I@
M UZ=BQ+'7J02VK5B2.O5K01NEGLV9W-BKUX(VHKI)II7LCBC:BN>][6M3=3;
M6="G@ SA9PDX=\/6I'UVE-)X?%Y!\2[QSYAM5DV;M1JG9R6\O->M-[]DEVW7
MO(CZWMI=G@TXZ?E9%^K7C72MZ7^_*K\GM1,74KLWM=H9&2UK'%HW4_"R^6['
MO_!PM\5]>FGU" "N99X               &KE\LW]E/QN^Z^+Z!PQM&C5R^6
M;^RGXW?=?%] X8E[J;_A^5]#?V])#/79Z.Q?IB^QM/,D %BBLH !\SY'S/D;
M&?S;'[%32_W4Z[_K->/>D\%O-L?L5-+_ '4Z[_K->/>DIUTM]*;0^F9/VLB[
MW0[T3LWZ%C?91  .>.D
M !_"<4OX,:C_ )"R_P!'V#^[/X3BE_!C4?\ (67^C[!^E/GQ^5']:/SM\R7R
M9?J9IWL=^]X/XF+^@TF$/'?O>#^)B_H-)A>*/?[64"7-^U@ 'T9(M[]PF_BI
M/Z"FWVZ.GUOM"?<;ICZ$HFH)O?N$W\5)_04V^W1T^M]H3[C=,?0E$A/KG^];
M/^<R?V:2>.HW[[M'YO&_:N/V0 $!EB
M             8MOG67UG.'WWQ6_U?RIE)&+;YUE]9SA]]\5O]7\J==T#],8
M'SW]R9Q/6/Z#VC\POM(&"" "W*Y(IG#D  9/H]E_(!?94\._XG4/T-9-ER:T
M;R 7V5/#O^)U#]#639<E;.M[TG5]$K^UN+0]2WHN[Z99]E2  142^
M                    #^ XK_P6U+_(&9^CK)_?G\!Q7_@MJ7^0,S]'63]*
M?/C\J/ZT?G;YDODR_4S3YS_NDG\9)_3<4BK/^Z2?QDG]-Q2+R% 8<E[%^H
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M%]W:>;='V[ZWVNY61+:=5&W%E[*KJD];<)^YYK7CV:\JB6G/3LWN:]\JY'<
M$=DF
M             '"G@/Y9SR,N&X[X.SK715>IAN+N%K/FAG9"V*IK>E7B<JX'
M,N8K.KR*HUOU'S+DE=!*WW#;CDIV4FI>_)PJ&QV5M6_"OAD8\W"R#_FRC\*$
MX\I0DN#3]JT:36KVQL?'S\>S&R:U958N7PHR7FSA+G&<7QC)>QZIM/3B9S!W
M<9=N8W)59Z.0Q]J>E>I66+%8J7*LKH;%:>-VRLEAE8Z-[5[G-[-TV4M9E0^<
MW] NMI/66'XVZ;HLK8G7DOU)UE!78UD,&KZE=7T\RD4;4;']7\;"Z*_(J-;)
ME*#;,CI;F5F<8KQ;SH]MJO:&)3E5K161\J.NKA9'R;(/Y,D]'\*.[+O*7=(]
MAV;-S;\.SCV4O(GI]\JEY5<_#RHM;R^#)2CW  &[-(#W%\WEZ0LFANDKIO&/
ME<S&\0,=DM'76<R,C=8DA7*XN257=FT=S'(UJ=[GRM8FW-N>'1^K<!>)CM%:
M[T7K%LCX_P!2VK-.Z@D<Q515KXG+U+MJ-=G,58Y:T,T,K>9J/CD>U7-W54U6
MW,!96'DX[6O;4V02_'<7N-<N*GNM>M&VV#M%XF;B9*>G8Y%4Y/EY"DNT3X/A
M*#E%\.39M^@4H94>QCTV5'M:Y-N[9R(J;>SM*I2PO4
M                        4GE-4W*ST*0!27N3Y"BO>GR>/E*WH^<I._
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M 544 K-7L.[5[2EZ?8I4 ) .K5[#L87@  #(
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M:\.*?%,NUL+;5.T,2G+H?D6P3<==77-<)UR_&A+6+\=-5P:  -4;<
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MQ(Q:\]I5EZWNEBRLB.S:):TXLMZ]KE/)W=%%-<U3&4HO_62DM-8)G( )>(9
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MDGCJ-^^[1^;QOVKC]D ! 98@
M      &+;YUE]9SA]]\5O]7\J921BV^=9?6<X???%;_5_*G7= _3&!\]_<F<
M3UC^@]H_,+[2!@@@ MRN2*9PY  &3Z/9?R 7V5/#O^)U#]#639<FM&\@%]E3
MP[_B=0_0UDV7)6SK>])U?1*_M;BT/4MZ+N^F6?94@ $5$O@
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M<6$U)*46I1DDXR33336J::X--<4UP:  ,'T
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MK$<K-7<PS!V !D
M                              HO=\Q55=B@?*\?R X52FB]F_I.SNWL
M.CE^1#Z!T<O84G=G8=E[5W]"%!Z_. 4E7TD5[OG*[U(<C@"A(I!>[O\ 'CL]
MA)>[\A!E=Z/'M^< C/=\Y;I7$N5WY"W2J 1I'%KE<3IG%KE?X_  1)7=_L+9
M(OL[O'X]_D)DKO1\9;7N](!&D=W_ "'\AK75M' 8?+9[*3LJXS!8O(YG)67_
M +G6Q^*IS7[MF3_W(*U>61WHY6JNZ;*?U;U/$[R]/2'9HO@)F,'!/U>5XAW*
MVE*K&K[]V->Y+N<<FRHY&K0K+6?[US7QV9(W*WF0V6Q]G2R\K'QHZZW6PK;7
MP8M^7+^;'63]2-7MK:4</#R<J6FE%-EFCY2E&+<(_P Z6D5ZV8,_&CBM>UUJ
M_4VM,GS-O:HSF1S<\;G<R5TOV9)H*;7=ZQTJRPTXE557JX6<RN7=5_-0@+I5
M51A&,()1C%*,8KDHQ222]2227J*+6VRG.=DY.4[)2G.3YRG)MRD_6V]6  ?H
M?  .CWHU%7U(J[)WKMZ$3TJ!J9A?FR?!1*^E^(_$2>%S9,MG:6C\;*Y-D=5P
ME.#+91S45N[XWV\M0B9(UW(DE6Q&J.<B\F4LSN/@7R8G '^YIP)X<Z6E@ZC(
M,P<>8S+%VY_JUJ*67-Y)'O[Y$BL7EK0N=VMKPPQHC&1M:GH!&G:B%.NEVTUE
M[2S+T]82NE"MZZZUU:5P:^5&"E]9=GH9LIX6R\+':TG"B,K%III;;K;8M/Q9
MS<?7IR7)3(4^9-OQERB:0H6]B>WM+E$G<<X=.3X4\? 7"-")$FR$^-/P $Z%
M/'S%PB3Q\)#C0GQIW>/8 2V)X^$FQH1F)\Q,C3YP"NSN)C$^8CH2$[E^0 JL
M[BKMV)[5*;4[BMZ?@3QX]@!W,8/SJ+ZR^B/O@P_0]\R?#&%\ZC[."^A_O@0_
M1%]3K.@OI? ^?7[,CC>L+T)M+Z-+]<3 Q !;PIB   91GFJ7UW^(GW!5OIJ$
MSQ# [\U2^N_Q$^X*M]-0F>(59ZT/3%WS6/\ 91+;=4OH3'^=R?MY@ $>DE
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M])3KI;Z4VA],R?M9%WNAWHG9OT+&^RB  <\=(
M                   #^$XI?P8U'_(67^C[!_=G\)Q2_@QJ/^0LO]'V#]*?
M/C\J/ZT?G;YDODR_4S3O8[][P?Q,7]!I,(>._>\'\3%_0:3"\4>_VLH$N;]K
M  /HR1;W[A-_%2?T%-OMT=/K?:$^XW3'T)1-03>_<)OXJ3^@IM]NCI];[0GW
M&Z8^A*)"?7/]ZV?\YD_LTD\=1OWW:/S>-^U<?L@ (#+$
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M?T%-P!P"_@)HK[DM.?0],A'KH^][.^7E?LXY/G49Y^T_DXGZ\D_6@ 0*6$
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M6L1LF@L02,F@GAD:CXY898U<R2-[%1S'L<K7-5%151=R80&6+3
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MQWH*AA   R
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MG%Z2A.+A*+\'&233]J)GQ\FNV$;*IPLKDM8SKE&<)+QC*+::]C.0 ?D?L
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MLYP^^^*W^K^5,I(Q;?.LOK.</OOBM_J_E3KN@?IC ^>_N3.)ZQ_0>T?F%]I
MP00 6Y7)%,X<@ #)]'LOY +[*GAW_$ZA^AK)LN36C>0"^RIX=_Q.H?H:R;+D
MK9UO>DZOHE?VMQ:'J6]%W?3+/LJ0 "*B7P
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MUW4^9W_5GL669M?&\G6K%?NJU]R[+C4N6FLKG7HN#T4FN,3(A0Y.$.2J)<$
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MNQA@K@X13D)_E  !D
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M\1/N"K?34)GB%6>M#TQ=\UC_ &42VW5+Z$Q_G<G[>8 !'I)0
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M;FV1TMO2X03T;IIUXJM->5+12L:3DDE&,0 .&)
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M_D#[M>T_Y/A?FW_YQLLOUP/T3_MG?_3&J_\ @P_7 _1/^V=_],:K_P"#&M-
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MT%-OMT=/K?:$^XW3'T)1(3ZY_O6S_G,G]FDGCJ-^^[1^;QOVKC]D ! 98@
M                                        &+;YUE]9SA]]\5O]7\J9
M21BV^=9?6<X???%;_5_*G7= _3&!\]_<F<3UC^@]H_,+[2!@@@ MRN2*9PY
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M%5QCJE)R+>]7'1']RL).U:9>3NV9&NC<-%[W3JOP:;WM-=;)2T;2B  <(2$
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M)HJOKXUW5PLA\F<5):^M:Z/P::*,[0PK,:^['M6EE%LZI_*A)K5>I\UZFF
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ML1SLUQA@K  )@  R
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ML>G&+7?&24EWI$$Y^SK\2QTY--E%L><+(N+T\5KPE%]THMQ?<SN #VGB
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M?GF!Y%[[%S@M]QE'_:3'I^4MV]_#LSZ5D?:R+T]'_P" 87T7'^R@  :DVX
M             /X3BE_!C4?\A9?Z/L']V?PG%+^#&H_Y"R_T?8/TI\^/RH_K
M1^=OF2^3+]3-.]COWO!_$Q?T&DPAX[][P?Q,7]!I,+Q1[_:R@2YOVL  ^C)%
MO?N$W\5)_04V^W1T^M]H3[C=,?0E$U!-[]PF_BI/Z"FWVZ.GUOM"?<;ICZ$H
MD)]<_P!ZV?\ .9/[-)/'4;]]VC\WC?M7'[( " RQ
M                       ,6WSK+ZSG#[[XK?ZOY4RDC%M\ZR^LYP^^^*W^
MK^5.NZ!^F,#Y[^Y,XGK']![1^87VD#!! !;E<D4SAR  ,GT>R_D OLJ>'?\
M$ZA^AK)LN36C>0"^RIX=_P 3J'Z&LFRY*V=;WI.KZ)7]K<6AZEO1=WTRS[*D
M  BHE\                           '\!Q7_@MJ7^0,S]'63^_/X#BO\
MP6U+_(&9^CK)^E/GQ^5']:/SM\R7R9?J9I\Y_P!TD_C)/Z;BD59_W23^,D_I
MN*1>0H##DO8OU   ^B+>_<)OXJ3^@IN . 7\!-%?<EISZ'IFG_O?N$W\5)_0
M4W ' +^ FBON2TY]#TR$>NC[WL[Y>5^SCD^=1GG[3^3B?KR3]: ! I80
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MAL]QS,U1LS=-:Z^$J\77P?%3NTX.:\F'%0U\]D.0"*R70
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M_ 1T[?Q?D*C7>A>\ KHNW8IW*2+Z%.R+MV+\0!6:_8JD<[-=L8:!6 W!G4
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M#_6-Q-_YP'ZW:Z(GVL<A_K&XF_\ . ^Z_LW\%G?H<?\ ZD?<3VI_*<'\^_\
MZ<Q[O-45_P#._P 1/N"K?34/Y#/%//GHC>2VX(<"LUDM0\,-(VM/9;+X]N*R
M%F?56KL\V>BR=++84KZASF4K1*DS4?UL,4<O>U7\JJAZ#$,],MN4[1S[,JB-
MD:YPJBE;&,9ZPK47JH3G'35</*?#P)RZ#[ NV9LZK#OE7.R$[9.53DX-662F
MM'.$'JD]'Y( !RIUP                        ,<CR[GD@DXSX%W$KAYC
MX&\4]-5%6[0B2*%=<X"M&]SL:^1SXXVYW'IO-AK,JJEB/KL5,J)8K3U<C<X5
M#:;&VQ?@Y%>3CRW;*WR?FSB_.KFN&L)+@UP:YQ:DDUJ=M[%HVAC68N3'>KL7
M-<)0FO-L@_@S@^*?%=TDXMIZ;:S6E@EE@GBE@G@DDAG@GC=%-!-$]T<L,T3T
M:^*6*1KF21O:CF/:YCD1S51*)G/>5Y\WWO<4=9IQ(X+R83#9W/R+^K?3^7M/
MQ^'NWF1HV/4>,DAK6/<F0M,:V'+U&L2K=E9'DHVPWI<C+>\@/UL;TD__ ,MP
M^_TEM?\ "2SVS>L#9=]%=L\JJB<XK?IMENSKFN$HOQ6OFR7"4='HGJE4[:O5
MUM;&R+:88=^37"7O=]$-ZNV#XQESUC+3A.#XQDFDY+23QX#)G\UB^OIK'[W%
MKZ=Q)^;_ *V-Z2?_ .6X??Z2VO\ A)[,>1#\CYQ;Z/O$[4.K=>OTN_%9/1\^
M#K?43+S7[*79,G0MMZV&2C61L/55Y/V1'N7FY4Y=EW-/TRZ5;.OV9F54YE%E
MDZMV$(S3E)[\'HEW\$S==!NB>TZ-KX-UV!DU55VR<[)UM1BNSFM6^[BTOK,I
MD %92UH                             !3?&CD5KD16N145JHBHJ*FRH
MY%[%14[T4\>NEUY"WH]<6WW,C-I./16I+?6O?J'0S8,%+-9D3MM7L7#"N&OS
M*]72RRS44GLRN5]F>93V)![L#:61BS[3'NLIG\:N;CJEW22>DEZI)KU'@VCL
MO&RX=EE457P^+;",TO7'5:Q?KBT_68"W2D\U_P",>F'3W>&6<P7$O&HZ1T>+
MLSP:4U3''NJQ1HW)SIIZ^Y&)M)/]6,6Y\BM2*CLYW)X.<:NB7Q0X<3R5]=\/
M]6:6?$BN?+E<-<BI\B+MUC<A''+CY(E7]K-':=$Y.UKU0VY>Q;LMAJ=^!]6]
M5K7:LG9)6MP168)$3_KPS,?&[_\ .:I)6R^MS.J2CDU5945\-+L;7[7%.OV>
M]+UMD6;7ZF-GW-RQ;KL23Y0X7TKV1GI9[??7ZDC3?-D:Y-VJCD]:*BI\J'9%
M-I;QN\D+T;>(*S2:CX2:72W8>LDV2P<-G2^5D>J[[OR6F[&+NO1%[48^9T?>
MBL5JJB^5_%#S5[@;DY)Y]+ZRXDZ3EE5RQ4WW\%J'$5?>;,;'#D<)%F9&M=LY
MW7Y^5SF[L1S%5'M[O!ZW-G6??H9&.^_6$;(?5*N3F]/76ORD>Y_4SM2MOL+,
M;)AW:3E59W\XV1W%KP7"R7%\=%Q,",&7QKGS3;.QN7]3/&;%6F?XJ9[2EJB[
MT]BKCLK?3L][[Y$[??+R)V(?+VJO-;N/-19$Q>I^'N71O[FONW*8])?V5&+^
M^*$BL_8_V7M1>W]C_;+NG1T]8.Q[--,ZM:_'A;7^7?KBE^4YK(ZN-MUZZ[/L
MDEWUSILU]BA9)O\ (8U ,@6?S9SI/M>YK*W#Z1J+LC_U82LYD]"\CL,JM^!5
M4Z?K9[I0_P#8^'W^F4G_  4]7_C79/\ +\;](CR_^!-L?Z.ROT?_ .S']!D'
M4O-E^DW(KNNCX>UT1$5J_JMGFYO6FS,.WEV]:[[^H_;=,^:M\:+2K]4M=</\
M2U%7943-9!7(G+LJ-AJQ(BNW=LBN3;E[>]#\[.G.R(+5Y]'\URF_R0C)_P!1
M]U= -LS>ZMG9"?C)0@OSIRBOZ^'>8PAQOX\>/E,QG0WFF=AW*[4_&ED.VROB
MP&D.OY^WM:R?(YB#J]V]SW5YMG=BQJBGW+PO\UOZ/N'DBL:CS_$G6;V\O74K
MV=Q>$Q,O*JJJ-BTY@\;F(DD1>5__ )=D<B-18G1KS*[4Y76AL>M/=OLN:[JJ
M+./L=D:X_P"\O:C<XO5-MJW3>HJH3TXVWU\./'A4[9<.?+ERU? U_KYFM3=R
MHU/6JHB?*?2G!7H>\5>(TT<&AN'>K]3++RJR?&X2XM%&O79)),E/'!CHH=_V
MT\MID+$[7O:ALN>"7DI>CMP\6O)I;A)I&M;K?N.3R5%VH,NWV.RV?ER>1>GI
M5'V7;KVKNJ(??6-Q=:G"RM3KP5:\2;1UZT,<$,:;[[,BB:UC$W7?9K43?M.0
MVAUR16JQ<.3\)Y$U'\M=>]]J=ELSJ/GP>9GI?&AC5Z^'*VW3OU7WGP?#D8$G
M1?\ -?>,>IO<U[B9GL!PUQKU8^7%59HM5ZI5G-[^*1N-F33M%[F;+%.S,Y?D
M<JI+41S>4R4.B9Y!WH[\*TJW7Z3BU[J&LZ.5N=UXR#.=58CWY9Z>&EB3"5'M
M=R21O2C)-!-&V:":)Z'LQL<D<[8Z>[3S=5/(=5;_ (K']YAIX-INR2]4YR1)
MVQ>KO9.#I*O%C=:OX[)TNGKXI279P?KA7%E&&!L;&QL:UC&-1C&,:C&,:B;(
MUK6[(U$1-D1-D1.XK ''';@                           M.;P5')T[.
M/R5.KD*%R%]>W1O5X;=.U7E:K)8+-:=DD,\,C%5LD4K'L>U5:YJHNQ=@93TX
MK@UQ37#30PUKP:U3X-'@!TM?-R> ?$)+-[2=&SPLSLO,]DVDVQI@'2<KU1LN
MF;".H00ND5G-'C%H(R-G) V-7*IC0])_S<+I$Z"?:MZ7H8CBG@H>=\=K2MR*
MAGVUF-1>LMZ7S4U:=TSG;LCJ8'(:@G>B([D;NJ-V+IQL=QL;K$VIAZ15WNBM
M?Q>2G:E[)[T;5IW)3W?Q6<!MSJRV3G:R='N:U\>UQ=VIOY5>[*J6O>W7O>$D
M:?'B5PEU5HRX_'ZOTUGM+W8Y'1.K9_$WL5+UC/VS&I<AB:]S?2D;G[=R[+V'
MYVC_ %>/'Z#</ZVX<:>U+5=2U#@\3G*CV/C=7RV/J9"+DD39[49:BE1J.1$Y
MN7;?9/4>5?&SR"W1<UNLLTW#:MIB](CN6_HC(Y#2[HG.7=TB8ZA.F#GD<[WR
MNN8JSV[JFV[MY'V=UQT2T65B6UOOE1*-L=?'=FZY)?SI/GS(QVGU(Y,=7AYM
M5J[H9$)52T\-^OM(M_S8+ERYFLW!G&\0_-/>'$ZN727%G7F(3EW2/4F-TWJ5
M.?M7E23%TM).9%MLUO,R:1B(KG/E7L/BK5_FHG$:!TCL%Q4T=D(VJG5LR6'S
M&.G>BN1.U8'W8&JC55RISJB[;)VJAUN/UD[&L_\ -[C\+*;H_P!:K<?ZSCLG
MJMVW7_Y-6+QJOHDN'J=D9>SR=68HX,B?/>;$=(^NYR4;G#W(M1J*UWZH;E)7
M.YG(K>67%2;;-1KN95V7FY=D5.W^93S9[I0_]CX??Z92?\%-DNFVR6M?=^-^
M?H_R-:HU?_@/;/%?N=E<'IYGZFGHUZUJC'^!D",\V<Z4"N:BU>'S6JYJ*_\
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M=&XG+LU$V1-UUANNR)Z5*OZW:Z(GVL<A_K&XF_\ .!8[[K^S./O.=S_!8_\
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MM-23.KCH-E;'GERR;:+.WC5&'8RL>G9N;>]OUPY[ZTTUY,O@ (R)4
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M[6.0_P!8W$W_ )P'W7]F_@L[]#C_ /4F?N)[4_E.#^??_P!.:U>ZJ]3-V?\
MHI/3_P"XIN N 7\!-%?<EISZ'IGE%)YNOT0W-<UW#'(*CD5JI_=&XG=J*FR]
MVL?4>SVG<!5Q6/HXNC&L-+&TZM"G$LDDJQ5:<#*]>-99GR2R*R&-C5DE>^1Z
MIS/>YRJJQUU@],L7:L<2./"^/82N<^VA7'7M%4H[NY;9KIN/773NTU[I.ZM^
M@^5L=YCR;:+/="H4.Q<WIV3MUWM^NOGVBTTUY/4O( (T)2
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M.S3V]G.>G_#O,=\&0%^MGNE#_P!CX??Z92?\%"^;/=*'_L?#[_3*3_@I^O\
MXUV3_+\;](C\O_ >V/\ 1V3^C_\ V8_H,CK ^:_=(>P]K;V6X?8YBOB17IF;
M]S9CEVD?RQ8V-5ZI-W<J=LFVS=E/H727FH7$&9T:YOBQI"C&NRRLQF$S%^9G
MK1JV9:43U1.[WR(OQ;GX6]/=CPYYU3^0K+/V(2/WHZN]M6+6.S[E\MU5_P!5
MED7_ %&)_N-S.!T%YISH"%6+JKB[K?)ILWK8].8?3VGW(NS>9L<V5AU2FV_,
MC7K6153E56(J*B^C'!WS>;HLZ16O-/H>]K&[77?W9K74&4S#)T]5C#UIL=IN
M5/\ ]"HOHWV[#0Y?6OLJM/LY7WON5=+C^5W.K1?4_8S?X?4]MBQKM%C8\>]V
M7*;7%=U*LUX:M<5R:;CJC6]Z?P5_+VF4<30NY6[)V,IXVI8OVG*J[(C:]2.6
M9=UV3L9\_8>I_1V\A_TF.)+Z\F/X<V],8F=6[Y[7=N#2^/B8]B/9,E*?W1J*
MY"]JIRRXW!76;]CG,5.S9$\+>COH+1%:&GH_1NF=,UJZ<L,6$PF/QR1-VY>5
MCJU>-[4V[-D=MMOZU/V/8XS:77'=+6.+B5UKDIWS=DO;N0[.*??HY36OBCN=
MF=2-$='F9MMO+6%$(TQ]:<Y]K)KNU2@]/!\5B:]%CS6#1F)=6R'%S6^0U?9:
MC7RX'3$+\!@VR<J*L,N0F?8R]YD4J<O6L^IS;$>_-5B54Y<DCH]]%+AOPHQ:
MX;AUHO3VD:,G(MKZCXZ"O;R$D:<K)\KD5:[(Y6RUFS&V,C:LS-8UL;7I&UK4
M^@P1IM?I-G9S_?6399'GV>NY4N_A5!1AJO'=U]9*>Q>BFS]GK]Z8M54N^W3?
MN?<];9[UFC\-[3P1UY3L :(Z$                  X5#S5Z6GDB^ 7&:2S
M?U9H/&U-0VD59=5:;8FG]02RKMM-=N8YL4>5E3E:U),K!=D;&WJHWLC5S5]*
MP>K#SKL>:LHMLIFOAUSE"7CIK%K5>I\#R9N!1DP=6135?6^<+81LCX:Z236O
MK7$PB^D]YJMJFC[JO\(>(&,SL#=Y(-/:VA?B,@J(JN=#7SV,@M49I.7:.LRW
MC:4;G(GNF_&USI&>"/';R8?2!X:K*NL.$^K*-:%51V2QU2'4>)5$7L<S*:<G
MRM'96[.Y73,E:U?V2-BHY&[6'8X5J*BHJ;HO8J>A47O14]/QDC;+ZV-I4)1O
M5.7%:<;(]G;HN[?KTC[7*N3?CSUC+:W4[LN]N6.[L.3U>E<E95J_&NU2DDNY
M0L@DN"7+3393L=%*^&5KHIHU5LD,C5CEC<G8K9(GHU['(O8K7-1R+WH==_9X
M\>K<VUG&#H1<(-?Q+%K/AKHO42;.VDR.G\;+88YR.19(K+8&6(IDYG*R:.1L
MK'+S->B]IY8<6?-K^B_J59'XS#ZNT//*O,Z;2.K;:M1_,JJZ*EJFOJC&P(J*
MC.K@HQPHUJ*R)KU>]_=8/7!A3T5^/D4-]\-RZ"]KUKGI[(-D>[0ZD\^&KQ\K
M&O2UT4U.B;Y:<-+8:\^<TN"\=%KHP9L6M_--=*OYW::XRZFI_P#Y*'/Z:P^5
M5>U.R2UC;6#1NR<R\S:3MUV3E1-U/D[4GFHG$N%7KB>*>BKS$7]C9=Q.;HS/
M;S(B<RQ>ZXFNY5553FVW[&JITM'61L:?_G%#U3IOC_\ QZ?UZ>LYB_JOVY6]
M/<6_SXUW8\EP]MJ?'N6FOJ,4X&1EFO-@ND5 [:GDN'U]NSEYESEVI[Y%7E;M
M)C)%]^B(N_\ B[[*B['\<GFS_2A_['P^_P!,G_\ !38+IMLEK7W?C?7/1_D:
M3_J-;_X#VSJU^YV5P_$U7U--I_4S'^!D KYL]TH?^Q\/O],G_P#!3^PTYYL'
MTB[3V)D,CP^Q;7<G,[ZNW;_5\SMG;MAQD2NY&^^][^V_:ILHETVV2EK[OQM%
MX3U?Y%JW]2"Z![9U2_<[)X_B)+ZVVDOK:,<XXW,MS0GFG>L)I&+J?B_IVA"O
M(LB8+3F1R4[&KMSHGN^[C(W.;[Y$]\UJJB>^1%7;T"X1>:P<#\1+7LZNUAQ#
MUI+$J==19=Q.F,):[E<DL&*QDF>CWVV3J-20JC7+^V<C7MU&7UF[(K\W)E:T
MO-JIM;?J3G&$/RR7M-QB=5.V[6M<:%"UXRNOJ27KTKE9+D]?-[M# B9[Y[(V
MHKGR.1D;&HKGO>Y=FL8Q$5SW*O8C6HJJO8G;V'I)T7?)%=(3B]+6?I;AWE,?
MAYW*C]3ZM5-+Z?KQHO*Z99\BUN0OHUZM:L.%QN4MHCTD]S=2U\K-B7P \FOP
M(X7I&NB>%^E,3:C:C$R<U!,MF7M1$Y4FS.8??RD_+WM6:V]6N<]R*CGN5?MY
M&(B(B=B(FR(G8FR=R;=R)[$.&VKUQ2:<</$2YZ69,M7[>RJ:2?>M;9+7FFCO
MMD=2,4U+/S'+DW5BQW5KWKMK$Y-/EPJ@].37=C!=";S9#AMH]:F8XNY9_$K-
MQ\LKL'69/B=&UY457(Q]=LB9+,,9NC7K=G@KV%C:]U&-CWP&2_I726*P6.IX
MC"8S'X?$X^%E:AC,73KT,?2KQIRQP5*=2.*O7A8FR,CAC8QJ=B(?T((GVOM[
M+SY[^5?.UIZQBWI7#Y%<=(1^J*;[]28]C='<+9\.SP\>NE/SI16MD]/PEDM9
MS_G2:7):(  U!N@
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M^<GQ/ +O&_Q[/R$ICO'CU%KC?M\!,8_Y%\?-^  N;'$ECO06UCB2QP!<&O\
M65T[?A]!":[UE9K@"4UWH7O*J.]"D;?YBJUWH7O *Z+MV>CT*=RBB^A>X[;[
M>U "LCMBJBD=%.R+L8:!7!U1Z'8)^(  ,@
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M                                       '&QR  #C8Y
M                                !QL-CD     XV.0 <;(-CD
M                                         XV.0 <;'(
M
M
M
M
M       .-CD       '&QR
M<;#8Y
M                  !2>GI.A7<FY0,)@I;=BIZBDY.PKN[%W*:F04'>OY2,
MY/02U3T>ON^$CO0 A/;Z"'(GI0N+T])$>WYP"W.;X\>H@2-]!=7H0I6^/'K
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M[;L4J P2-P4$4J(_UF =P -0  9
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MX1/0=N]=O0@!4:FR'=B=IU*K$[##8.X "0  ,@
M
M
M
M
M
M
M
M
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M%'??O^4Y3L^  K([8J(\H(]#L8T!(W!013LCP"J#JCD.QD  #4
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MFQ"H8  !D
M
M
M
M
M
M
M
M
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M;(=T3<X*C$](9@J
M
M
M
M
M
M
M
M
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M+9/'CN+.R0E,D]0!=6O]16:_XBV,D^+QX[B0U_S^/C +DU_K*S7EM:_8K-D
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MN+UPJY)^7-?^9:?#<B_O//>DNT6BC!RE,;Z?1X[2=#'Z3I%'NJ>K\9<&,]!
M98L[L9\A<(F>/:4HV=WCXRXQ1@%2-A.C9^<IL;^8G1L\>L J1,\>PGQM])28
MST?*36-]'J[_ !X[0"I&WQ\Y,8TIL82V-]/R %1C?026IZ#HUNQ(8WYP#NU-
MOB*K4^<Z(WM^ K-3< [)V)OZ5[CNU-CJG:OL0J '*)N5SHQ#N8  !D
M
M
M
M
M
M
M
M
M                                                     &&"D]#H
M5U3<H*$_Z@4O8OQ'14]!5<AU7M[?E,@C[>CTIW>TH/3TDIR>E.]"FY-TW^4
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MA58GI^0 [(FQ4]&WI4-3TKW'9J>GU@'9$V.S4W."LU-D#!V
M
M
M
M
M
M
M
M
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M#JQ/22$[/A ")OV>@JHGH.$38J=WPK\P!SW]GH0J'#4V.R)N =F(53A$V.3
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MH_6HJE_[WU&XPNN[-BU[HP\:Y=_92LID_9O.Y?[IN3!N:S?HE^73Z0W"F:I
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M7#7D9\_ZZ9X&?Y*\0/YOQO\ Q ?KIG@9_DKQ _F_&_\ $# 8!U_W*=D?$O\
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MV=ET"ZQ-I;0VG3BY,J75.%TI;E*A+6%<I1\K>?>D9=( (,)^
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MM5PL=&0__+WZ0E)^%<TW79ZE&6_IQ<$CU=!QN<G%'=@
M
M
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MHUKZNXRGHTUP:>J:X--<FGW-/BO7Q,T;R1'G#WU3L8KAIT@<E!#=E;%C]/\
M$ZQU=>O=G3DBJT-9*U(X*UJ=/V.+4+6LKV)D;]5&Q2S/NNS!8)V2L9)&YLD<
MC6OCD8Y'L>QZ(YKV.:JM<US516N151R*BIV&FQ<U%394147?=%[45%[TV[OB
M[C+U\@=Y:2;&6L/P*XLY9TN,N2PXWAYJW)6.9^/M2O2.KI/,6YE5SZEF1S8L
M%>GDWK2JW&3O6.2HL<%=/NKN,8SS=GU[NZG._&@N&[SE93%<E'G*M<--7#33
M=+ =776;*4J]G[2LU<FH8^5-K5M\(U7R>FK?*%CXMZ1FVWO&:\#A%.2#2P
M       !BK^=?_6GX6_?,E_JCGS!7-@+YRYP UQQ#X:<.,=H72F;U9?H<09;
M]VG@Z,MZ>K2_4QFJWNJ9D:>\A]T3Q0\[NQ9)&M[U,-S^]F=(;[3/$'^8+/Y"
MRW5GM+'JV35"R^FN7:WO=G;7"6CL>G"4D^/=P*M]:^S<FW;%DZL:^V'84+>K
MILG'51>JWHQ:U7>CX=!]Q?WLSI#?:9X@_P P6?R#^]F=(;[3/$'^8+/Y#O\
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M[?\  ?#H/N+^]F=(;[3/$'^8+/Y!_>S.D-]IGB#_ #!9_(/W:P_Y5C_IZ?\
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M]#9'R\?[:!)/5-Z<QOFLG[&1ET@ JP6X
M  /*SRVWV+/&/[EW_P"^536!&S]\MM]BSQC^Y=_^^536!%BNIW^ Y/TI_95%
M9NNWTAB?1']M,'"]RG)PO<I+KY,A=\F9NGFFG\"^,OW6:9^AKIENF)%YII_
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ML/DL6K#T:CI[,\DDT\BNEE>Y[G.6Y %1V]2YR6G!=P !@R
M
M
M
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M.-G[426/<H7:>5C7:0O7CI'5JQ+XU<II=^G(^PFR+\7CXBJU_J7;QZBV-?\
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M:LN6FB??"O=33W9.:YO2JKVJJJJJO:KE7O5RKVJJ^E5W5?2 "22,
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M4^"WW,6/IS+&L"-G[Y$3[%/@M]S%CZ<RQ$/7'_ <7Z6OL;2:>I'^'Y?T3_\
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M@?LFKWWJ=7_3VC386E8NM?TL_H]/Z["UO4]Z&C])R/UQ  (T)3
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MQ&X;?RGQ%_\ $G5A[=E-^E/I/:/T[+^WL+Q]%O1FSOH.)]A6  :$WP
M/*#RX?V+/%[[GXOI*D>KYY0>7#^Q9XO?<_%])4C;]'_X?A?2L?[6!IND7H_.
M^B9/V,S6&IW(<G"=R')=!<D477)'*=Z&;-YIA_!+C3]TND?HC*F$RG>AFS>:
M8?P2XT_=+I'Z(RI'_6AZ&R/EX_VT"2>J;TYC?-9/V,C+I !5@MP
M                     >5GEMOL6>,?W+O_ -\JFL"-G[Y;;[%GC']R[_\
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M%1DX+A5#1-\(1U;X\9RDUHFD@ .3.R
M
M
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M'^^!#]#Y R@3%^\ZF^LQH?[X$/T/D#K.@OI? ^?7[,CC>L+T)M+Z-+]<3 P
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MZ$/UG.%OW Z4^A*9"G7-]YP?G;OV*R=>HW[_ +1^:Q_VK3ZC ! 18P
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MAZMQZ6?5V4IM^.B\"1.JW:KQ=L8\6](92GC3XO36:4J^')OM802\%)Z<S/U
M!58MX               >07E[/L2>,7\GZ8_KUI<UEALT_+V?8D\8OY/TQ_7
MK2YK+"R'4]Z-O^G6?V?&*N]=?I;'_P#3JO[3E@ $KODR('R9G&^:=?6XXM?=
M[C?ZMTC+#,3SS3KZW'%K[O<;_5ND9894CI]Z8SOG(?95ER^KGT)L[YF7VM@
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M/_2W;/6VI>W]TF<B=B;'[:4\Z4[>GM'-NR)-[FNY3#NA3%M07M?GS\9RD^7
MNST1Z.U[+P:<6*6^EOWS7\9?-)V2]B?DP7=",5Q>K8 '.G3
M           &*WYU]]:3A=]\]W]3]1F"F9UGG7WUI.%WWSW?U/U&8*9:+JL]
M$5?.W_:2*F=;OIJWYC'_ &&#A?1X]"G)PI(DN1&+Y&R6\W4^Q&X;?RGQ%_\
M$G5A[=GB)YNI]B-PV_E3B+_XDZL/;LIOTI])[1^G9?V]A>/HKZ,V=]!Q/L*P
M #0F^      !Y0>7#^Q9XO?<_%])4CU?/)_RXB[=%CB]]S\7TE2-OT?_ (?A
M?2L?[6!IND?H_.^B9/V,S6')W(<G"=QR707)%%UR1RG>AFS>:8?P2XT_=+I'
MZ(RIA,IWH9LWFF'\$N-/W2Z1^B,J1_UH>ALCY>/]M DGJF].8WS63]C(RZ0
M58+<                              'E9Y;;[%GC']R[_P#?*IK C9^^
M6V^Q9XQ_<N__ 'RJ:P(L5U._P')^E/[*HK-UV^D,3Z(_MI@X7N4Y.%[E)=?)
MD+ODS-T\TT_@7QE^ZS3/T-=,MTQ(O--/X%\9?NLTS]#73+=*E]87IC-^55]A
M47'ZM/0>S_F[/M[0 #C#N@        #Q0\XB^Q"XI?Y[PW_\4]%&M<3O7XC9
M1^<1?8A<4O\ />&__BGHHUKB=Z_$6/ZG_1MWTZW^SXI6#KM]*8OT&'V^0=@
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M26L*V]-=*8RW=.6]OR7G,  XL[H
M
M
M
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MPARDA 1_9OLNWK]!RC_::TV9<$D3QN=^L3U_/^4M_.ISS@%PY_4J_,=N=?\
MK+\A;NL]ASS@%PZQ?6GSCK%]GR?F+?SH.= "X=8OK3Y/S#K5]:?.6_G0<Z $
M_G7U_)^<XYO;\R$'G0XZSV $[K/&Z'59$\;D+K#A7J 3.L.BR*0U?[3CF]B_
M( 2ED]IT60_-]><6M*Z5K>[=4:GTYIFDJJB7-19W%82KNW97?X1D[=6'WJ*F
M_O\ L1=U///BEY:/HW:5;(DG$>AG[$2JBU=)U+NH'N5-^V.U4A;CI454[%CO
M/3T_M513WX>RLK(^\8U]W'3WJJ<U];BFD:[-VOB8W\(R:*-%K[[=76]/'24D
MSU1YU.BO]OC\'CL0Q>N,'G,FDZB2PZ%X<YO-S-5R1W-1Y*M@Z+VJFS)&Q5(\
ME>W:N[G1/AB1VS6)*S=7M\G>-?E]^D1JM)(,1F<'H&A(KF]3I3!U9,@^%W[5
MDV9U F9N1RM[_=&*3$2*J(FR-5[7]EL[JQVM?HY50QHOX618HO\ ,K5EB?M@
MOUZ</M/K7V-CZJ-\\F2^#C5N:_26=G4_YLV]%RY:YY.HM4XW$5G7<M?HXRG&
MU[WV<A;@IUT;&U7O7K;#XV+RM3F5$55V[DW/*;I!>7 Z/6@4G@;JN?6V5A1R
M)B="TVYISI&KRK'+E9[%#3]9S7^]D9-EFSM3=6P2<JHN!MQ+XW:RUI8?;U=J
MO46IK$KD?))G,Q>R*.<B]CECL3/B16JG8K8TVV3;N0_+T1$[$3L3N3U'?;+Z
MG:(Z2S,J=O?V=$57'V.<M^4EW<(P>G>F1YM7KNOFG'"PZZN&BLR)NV7J:K@X
M13[^,[%ZGWY+G2$\Y0UQEO=%3AMHO$Z3JN161934-A=09CE<Q6.D2K RGC*\
MB[K)$W_"NI?RHLLS6JY_A%Q\Z5?$?BE;;;X@:RSNIUCEZ^O3OW'-Q%.;E<Q)
M:.&K]3BJDJ1N6/KX*C)WL[))7[;GX""2=D]%L#!T>-C55R7\8TYV_I;'*:U[
MTI)/P(MVQTMVEGZK+R[;(-Z]DFJZ?5[U6HUO3N<HMKQ.J-1.S;L.P!T!SN@
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M?I)4<149$3(XO'CN .D<7C\A-9'L=V1^/426,_. =6,^7\!+9'X_(=F1DQC
M#JQA+9'Z0R,EM9\OCY_8 <,9X\?-ZR2UH:STJ26M]( :TD-;Z0UGK*[6[]H
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M*X1BN27>]67#V1LC'P<>O%QJU756M$N;DWQE.;YRG)ZN4GQ;]6B  ->;(
M      &#!YV!]<[A/]PF9_K AG/F#!YV!]<[A/\ <)F?ZP(=_P!6/IC'^1D?
M86$<]:_H++^5C?VFHQ34[D.3A.Y#DM25$7)%&Q^YO_[COZ*FVSZ$/UG.%OW
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M[;'K^/.4OZM="]^R,-8^+C416BIHJJ7/X%<8]^KXZ:\7JWQ?$  \!L0
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M!3KG&4)PDM5*,EI)/U-<#1X^1.JR%M4G"RN49USCPE"<6G&2?BFE_P 3; ]
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MG07]+5!AUF8IYI9^_..7\3H+^EJ@X7K)]"YG_L?VBHD'JN].87^T?V6XS/
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M]B$H I07N0
M
M
M                                                    *+F[%8&&
M".4U3;M0K.;L=3(**IZ4[OP%-S=RLJ;=J=QU5OI0 C[;_"4G-)*MW*;OG_"
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M+FLL-FGY>S[$GC%_)^F/Z]:7-9860ZGO1M_TZS^SXQ5WKK]+8_\ Z=5_:<L
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MTUTY]N//_P"CF-_M(^Z?L?\ E$OT-W^6/N4;<_DU?](I_P 1Y2^;0_914?N
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M3TBLNJ+?#@K'V;;UX)+?U?J7#CP-G<BG(!3LNT
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ML'7;Z4Q?H,/M\@[  EDAXV$'FP7V-UC[X.I_]GC3(P,<_P V"^QNL??!U/\
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M*H[GJY"G6O5G]GOZ]N%D\+NQ53WT<C5[%5/4I>"D[6G#P+WIZ\5R8 !@R
M
M
M
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MBW+PKL>;KOIMIL7.%M<JY?DFDSN #TGF
M                  .'+LFZ]B)WKV?CV/WS@CT6.)'$FVRGH/1&HM42O_\
M2XW'O2A&F_+SV,K:6MBZL2.['36KD,+%_;2)Z/QOR*ZHN=LX5P7.<Y*$5[92
M:2^MG[8^/9=-5U5SML?*%<)3F_9&*;?U(_!#HZ1$VW[-U1$]JJNR(B=ZJJ]B
M(G:J]R*9-W1B\VRUGE?<]_BOJJAI6J[E?)I_3*QYO-(U6H[JK65>C</5E:[=
MDC*292-6KS17$7L,BWHO>2^X)<(UKVM*Z(QEC/5TW;JG4$;,_J)CU39[ZE[(
M,E;BE<BJUWU)AHJZ->KE61%4CO;76CLW&UC3*698NZG15:^NZ7DM>NN-B)*V
M'U2;4R])7J&#4^^[RKM/%41XKV6SJ9A<=%+R-W''BLM6W7TXNCM/6.1_ZH-9
M-GQ4*P/3F2:IC.J=EKJ.:K71\E6-DC7MD;(L?OS)IZ(?D N$/#Y*V3UFZ?BA
MJ2+E>Z7-5F4=,U94_P"P:;AFL)(C'>^;-EK^2EYT22%M;=8T]X&Q^CN39$3X
M$[$3;U)Z$]!51B?"0_MWK'VEF[T(V>Y:7K[WCZQDUX2M^^/AP:BX1EWQ)KZ/
M]6&R\!QFZGEWK3WW)TG%/QA2DJH\>3<93C\?QM6)P]6C6AITJM>E4KL2.O5J
M015JT$:?M8X:\+611,1.YD;&M3U%T2/XR2V)?@^#O)3(40X)O7B^9(J\.XB-
MB5?'C\!+9"B$AL979$8!0:SV$ID7CTE9D7CTDMD(!09$2F1%=D97;'\8!39'
M^DD-C*K(_'H);(P"BR+V$IC-BHUGJ0E,C]GC\8!3;%Z_D)#8_'Y#NUGC\I):
MP ZM:5V,_2=FL^)"0UGQ '5K/45T38Y:WU(5FL .&L*NWR^HYV]7?Z_4=VMV
M #6_*5$3TKW!$]*G9$W[?0 $3?X$[BH#LUNX!PB;E9$V")L<F&@  9
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MGW\^8 !^1^H      ,&#SL#ZYW"?[A,S_6!#.?,&#SL#ZYW"?[A,S_6!#O\
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MTWD1EUI=*(X.SYT0E^^<V,J813\J%4EI=:US2W6X1?QY)KS7I\!HAR 6C*F
MR??-9^!;\QQ@UAKV:-5J:-TB[%U7NC58URFIKD+7*R3;9)Z]#&S)R[[]5==O
MWH8P*KMW]QL</-VNBM+PZZ.^&SF2J.JYWB=;EUO<9(U6S,PUG_!M*,?VKNVQ
M@HJ^6C[&N8W*]2]$=&I'O69M58^RKH)Z3R91QX>R7E6</#LXRBWW.4>]HD?J
MJV4\K;%,VM88D9Y,WH]$XK<J6O+5V34DN]0EP>C/>$ %62W(
M  !Y!>7L^Q)XQ?R?IC^O6ES66&S3\O9]B3QB_D_3']>M+FLL+(=3WHV_Z=9_
M9\8J[UU^EL?_ -.J_M.6  2N^3(@?)F<;YIU];CBU]WN-_JW2,L,Q//-.OK<
M<6ON]QO]6Z1EAE2.GWIC.^<A]E67+ZN?0FSOF9?:V  ''G;
M  '\WK+_ *'RO\FWO]UE-.)BOWK6_B(?]FTW'>LO^A\K_)M[_=933B8K]ZUO
MXB'_ &;2=^I;S=I>W#_5E$ =>?+9G^V?_C$\ $XE?C(C\V!^R:O?>IU?]/:-
M-A::]+S8'[)J]]ZG5_T]HTV%I6+K7]+/Z/3^NPM;U/>AH_2<C]<0 "-"4P
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M>DT-J8%5Z:[:"563#OC=%:2>GQ;/OD'\66C\J,DNP .6.N
M          ,5OSK[ZTG"[[Y[OZGZC,%,SK/.OOK2<+OOGN_J?J,P4RT759Z(
MJ^=O^TD5,ZW?35OS&/\ L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3X
MB_\ B3JP]NSQ$\W4^Q&X;?RGQ%_\2=6'MV4WZ4^D]H_3LO[>PO'T6]&;.^@X
MGV%8 !H3?       \H/+A_8L\7ON?B^DJ1ZOGE!Y</[%GB]]S\7TE2-OT?\
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M"2(
M
M
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MFZ*BIZT7L.AC)-)III\FGJG[&CG)Q<7NR3BUS36C7U/B<@ ^CYU &X
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M]9SA;]P.E/H2F0IUS?><'YV[]BLG7J-^_P"T?FL?]JT^HP 0$6,
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M2=D-7X0G."BWX;^XO6B.<3KKV=.W<MQ\JFMO17-5S2X\YPA)R2\=SM'ZC8_
M^-^@UTY]"=(#0];7&AKDJP),M#-86^UD.9TYF8XXY9\5E:S'R-;(D<D<U6U"
M^6I?J216JLSV.5&?9!%N3C64V3JMA*NRN3C.$EI*,ES33_[:XK@2]BY5=U<+
M:IQLJLBIPG%ZQE%\4T_^VN3X@ 'X'[@
M
M
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MORG*(5-MN_Y #AK=SGO39#E$W^#T;'=$ ")L<A$*S6[?"&P=6L]94 ,   R
M                           8OWG4WUF-#_? A^A\@90)B_>=3?68T/\
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M\^Y*OP</S5_R/KW5;^%L_23_ .9^D_W9]9_Y8:K_ -(\S_;1_=GUG_EAJO\
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M=J55I2E3FN-%U<8N3U>O96I+5ZU2;<M$_>W9PUT:V0 .$4Y*KEO@
M#%;\Z^^M)PN^^>[^I^HS!3,ZSSK[ZTG"[[Y[OZGZC,%,M%U6>B*OG;_M)%3.
MMWTU;\QC_L,'"^CQZ%.3A?1X]"DB3Y$8ODS9+>;J?8C<-OY3XB_^).K#V[/$
M3S=3[$;AM_*?$7_Q)U8>W93?I3Z3VC].R_M["\?1;T9L[Z#B?85@ &A-\
M   #R@\N']BSQ>^Y^+Z2I'J^>4'EP_L6>+WW/Q?25(V_1_\ A^%]*Q_M8&FZ
M1>C\[Z)D_8S-8:G<AR<)W(<ET%R11=<D<IWH9LWFF'\$N-/W2Z1^B,J83*=Z
M&;-YIA_!+C3]TND?HC*D?]:'H;(^7C_;0))ZIO3F-\UD_8R,ND %6"W
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MMN%.4U5KKY*G7"<HQ?+3>UEHN3E)OF  1(3*
M
M
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MB1>Q"?U7L^<[I#[/FW ("1J5$A\?H)Z1>PJ)![ " D7A$*B1>%+@D)42- "
MV%2LV$FI'["HD?Z$ (C82JD9*;%["LD0!$2,JMB\*3&Q>$*K8@"(V(D,B\>@
MDMC]GC\!6;& 1FQE=L?L)#6>S?Q\JE9&>/S?E ([8T\>-BNV,K)'ZBLD8!1:
MWV?!X[BJC"NV/XBJUGL *36?(5FL]151A41 "FUFQ51NY41GQE1$3T_(@!T:
MS])43V=OM]!V1-_8GJ.Z)Z@#JC?2O>=T3<[<J)W_ "'/?\ !U^ J(TY1-CD
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MO"U&105Z\+610Q1L1&LCC:UK6HB(B(74 CMO7B^9):6G!+1+@DNX  P9
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MD=7/07*V/;ESR+*+%?"J,>QE-M.N4V][?A#GO+334_J@ 1D2L
M #C8Y !_&Z_X>8'5>(NX#4V&QFH,)D8707\3F*-;(XZY"]%1T=BI;CE@E:J*
MJ>^8NV_9L8K'3<\UWTOEG6\WP+U _25Q^\K=&:EL7,IIY7KUBK%C<U*^SFL<
MQRJQ&17GY6*-$=R/CCY(F9;)QL;O8O2+,V?/?Q;Y5IM.5?G53T^/7+6+?<I:
M*26NC1H=N]&,':4%#,QX6[NNY9YMM>OQ+8Z3BO&.NZ_A19J@.E!Y._C5P<M3
M1:_X>:AQ=")VS-1TZ,V8TI8:KE;&Z+4>,99Q<3Y=N9E.[/3R+6JBRTX^Y/BM
MDB.3=JHOP*B_C-R=8KQRQOBE8R6*5CHY(Y&H^.2-[5:]CV.16N8]JJUS7(K7
M(JHJ*BGG9QU\DMT=N(JRRZCX5Z7;<F1$?DL+333^01$39>6SAEIN17=BO=MS
M/<B.<[F3<EK9G7&M%',Q&GWV8TDT_7V5G+]*_#@0UM?J0EJY8.:M..E65!^O
M1=M5]2^\KQX\C5D S]^(WFMO +*RR2X+4/$;22*B]56I9C&Y>HQRHFR/3/8G
M(W)&-5%79MV)Z[[+)V)M\KYKS2W!OEWQW''-5H-E_8[VA<??EWYG*W]FKZCQ
MC-D9RHY.HW<Y'/16M<C&=?C]:6QYI;UUM3\+*+6U^BC8OR-HXS)ZI=MUZ[M%
M5VCTUJR*EKZUVTJGI[>/#ER,+ &9[%YI1CT<U7\>+[F(YJO:SAU58]S-TYFL
M>[6,C6.5NZ-<L<B-7958Y$Y5_=-%>:D\):KFR9_B5Q$S*M<B]31CTYA*LB;O
MYFRM^I62N=J+&B+#=A5JM>J\R/:V/]+NL_8T5K')G9ZH8]Z?_P E<%_6?G1U
M4;<F])8L*O79DX[7_P 5EC_J,$U5V]2?"?IG"?@MK'7N3BPNA]*:BU?E953E
MHZ;PV0S$[&*Y&K-/[A@F95K,54ZVU:?#6@;N^::-B*Y-CKP=\@GT7M&OCGBX
M=Q:BMQJUZ6-6Y/(Y]>M8NZ2MKV["U(U1>YD<#(]_\3?=3U?T-P\P&F*#,7IS
M"8G 8V/M90PV/J8VHU=MN;W/3BAB5ZHB<SU:KW=[E53EMH]<=$4UB8MMC[I7
MRC5%>O=AVDI+U;T/:=9LSJ0R)-/,S:JH]\,>$K9>S?L5<8OEQW9KGPX)F#GT
M,?-@^(>I75,KQDSE?0&(=U<LNG<-+4S6JI8U]\Z">Y$Z?"8N3L6-[HI<JK.=
M)&<RL5BY@71$Z"G"S@9@_J%PVTI2P<<J-=D<I(LF0U!FITW5;&7SEUTV0NNY
MG.6*!9F4:;'>YZ%6K69' SZ[!%&WNF.?M'59%VE6NJHJ\BE>&L4VYM=SLE-K
MN:)BZ.]"MG;,XXU"=NFCR+7VES7>E)K2"??&N,(OO3.$0Y .7.L
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MDWP)^Z)[)LP-G8N);*$K**W"4JVW!MSE+R7)1>FC7-(  T)T(
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M:S@_GC,_VT?W@OHK?:S@_GC,_P!M'W8=G?@,O\RK_.'W%-I_RC"_/N_R#6?
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ME?AN-.13;)1G;O.-=L9M+6E+5J/#5I:GJ@#A%.2OI8\            '&QR
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M=&UKR;+&;%PY8V'B8\VG.C&HIFXZN+E77&$G%M)Z-IZ:I/3N0 !K#9@
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MGH^6A+W1SH+LW9FDL>C>NTXY%S5EW+1[LM%&O5-IJJ,$TVGKJ=>5#L <J=@
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M&,=7NPC&.KTU8 &A.B
M
M
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M^KO]8!PC?7V'*+Z$.R-]9VV .J,.X*B,]?R '5K=RJB;'(,   R
M
M
M
M
M
M
M
M
M
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M)L<G9&[@'4[M:=T:B'8QJ#A$V.0#(
M
M
M
M
M
M
M
M
M
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MLB;')V1J@'4[(W<J(W8[&-0=4:AV &GB  #(
M
M
M
M
M
M
M
M
M
M
M   !PJ'( *:L.BHJ%<&$".<*FY75J*=.0R"AU8[?A*JIL< %'L]J?@.>7U+N
M5-CJK "DJ>M#JK4*VRA?:GS@%#EV[E.JHOJ3Q\96[/TG/)\ !'[/:-O:5U13
MJJ)Z@"@L7L^0Z]7\)7Y$'*OK (W(<<BDE47V*<;?^Z 1N5?4=50E*B>WY#CL
M\( 1>5/4<<B>HF<OM0<OM3Y0"%R(.1"9R? HZOV?@ U(?(@Y$)?5>SYSCJ_9
M^$#0B\B#D0E=5[#GJO9\X,:$3D0<B$SJ_8.K]B?,#.I$Y$]0Y4]1,Y?:GRCE
M]J $5$]2'/*OJ)&R>OQ\QRB)[0"AR*<]7[2OM[/E.R(OJ1 "@D?PG9(O9\I5
MV7UA& '3E]J#L]JE3E3U'9$ *2)[/PG;9?65>11M[0"GR(=D0J(GJ3Y3GWWP
M '1&>OL'9\/X#NC#N 4TW]"#D]94 !PC40Y._(IV1B %-$W.Z,*@,,'"-1#D
M R
M
M
M
M
M
M
M
M
M
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M4ZOVG9&H8U!21J^H[(PJ@<?^_P#M?\0=.1#ML<@R
M
M
M
M
M
M
M
M
M
M
M                                              #C8XY4]1V !TY$
M..K*@,+4%'E4XV7U%<&01P2#C8 H K\J>HXY$]1C7_O_ /P%$%7D0<B#7_O1
M@I'&R>HK<B''5^T:_P#>C!2V3U#8J]7[3GD&O_>C!2!5Y$'(@U_[T8*0*W(G
MJ'*GJ&H*(*^WL.0"ALOJ.>5?45@9!2Y#GD*@,/4'7D0YV3U'("  !D
M
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MN6LX16B<HKGKQ/N( '/G2@
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MA5.Z=M:UH483A#=C8]-^3<TTX*4-$_+UT3]F@ <L=8
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M$56EJE9RL;U6G9J4.?E<-'[T  Y0[
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M>U<?-ICD8MJNIDY*,XJ23<6XR6DE%\&FN1R #PFP
M
M
M
M
M
M
M
M             !B_>=3?68T/]\"'Z'R!E F+]YU-]9C0_P!\"'Z'R!UG07TO
M@?/K]F1QO6%Z$VE]&E^N)@8&Q#\V6^Q@I?=WK+_>:AKO#8A^;+?8P4ON[UE_
MO-0FKK<]%P^ET_9WD%=3'IBSZ#=]MCF0: "M):<
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M4[ZN?36S_GG]E,V H *AES@                                 <'(
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M7]!,S9EN1E9FY"=M2IKIA)3:CO1G*<Y1\E/6,5%1<N<FVN!4 !$Q,@
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M1],7_-T?91)3ZIO0F/\ .9'VTP "/"20
M
M
M
M
M
M
M
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MXN<M$ZUJ]$]%KQ)TQ.MO95UM5,%E;]UM=4-ZE);]DXPCJ]_@MZ2U?<N)G.
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MYS(^VF  1X22
M
M
M
M
M
M
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M*TWWN,)*+?#5K4MMT/VT]H;-Q,N>G:65Z6Z+1=K7)UV-+N3G!R2XZ)Z:O0
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MIO0F/\YD?;3  (\))
M
M
M
M
M
M
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MS<EKRJ::ZH:]W;RE*37=JE2ERU2EP>C9_9  KZ60!\W],1/_ #2\3ON!U=]
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MS32?]1R #@"1@
M
M
M
M
M
M
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M,;7_  0?KL[/?:4Q?^F-K_@AB,_4:[_V&[_\G9__ '0^HUW_ +#=_P#D[/\
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M;%(C+K;]*Q^BT_MVDL=3?H=_2[_U5@MN9_>=O_-I_P#9.+D6W,_O.W_FT_\
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MI;&/UPKA!_D::)XZNJG#8FSTTTW2Y\?"=DYI_7%I_6  <>=J:C_IE_7CXO\
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MD5  1\20            <;'5C&M1&M:C6M1$:U$1$1$[D1$[$1/1L=P
M
M
M
M
M
M
M
M                                      #%^\ZF^LQH?[X$/T/D#*!,
M7[SJ;ZS&A_O@0_0^0.LZ"^E\#Y]?LR.-ZPO0FTOHTOUQ,# V(?FRWV,%+[N]
M9?[S4-=X;$/S9;[&"E]W>LO]YJ$U=;GHN'TNG[.\@KJ8],6?0;OML<R#0 5I
M+3@UUGG+WV45[[@-&_ARYL4S76><O?917ON T;^'+DF=4_I7_9K?VJR*^N+T
M,_I6/_?/ 6+]O'_&1_[1IN"N$7\$],?<]A?HVL:?6+]O'_&1_P"T:;@KA%_!
M/3'W/87Z-K'6=<_F;/\ E9/ZJ3CNHSS]I?)Q/UY!^A@ @<L*##C\[7_>W ?_
M #KB+_L-&F8X8<?G:_[VX#_YUQ%_V&C3N^K3TUA_[3_9;R/>M3T#G>W%_MF.
M899LR/($_8E<(_\ -=5?UYU,:S<V9'D"?L2N$?\ FNJOZ\ZF)3ZX/1U/TZK^
MSY)#W4EZ6R/H%W]IPSV( !7$M&>2'EU?L5>+?\CT?IG'&L=3T^/0ALXO+J_8
MJ\6_Y'H_3..-8ZGI\>A"Q?4]_ +_ *7/[&DK'UV>DL;Z%'[>\R]_-*?X0\>/
MY&X;?[[KHS6C"E\TI_A#QX_D;AM_ONNC-:(QZS?367[,?^S4DM]5OH/"_P!H
M_M-P !P1()_-ZR_Z'RO\FWO]UE-.)BOWM7_B8OZ#3<=ZR_Z'RO\ )M[_ '64
MTXF*_>U?^)B_H-)WZE_-VC[<3]605\Z\_.V;[,O]>.>XWF[WV56BOY'U9]#S
M&R9-;-YN]]E5HK^1]6?0\QLF3FNMSTG7]$K^UN.GZE_1-GTV[[.D&/UYS#IZ
M2YT7\G;9S<F(UIHR]-LB*G5SY-<4U7KNBM:DN2BV5$<O-RHJ(BJYN0*?#OE)
M>CE+Q8X'<2-"U8TER.7TW<DP[5:KO_+6.1N1Q7*U.USUNU86L;V<SU:G,W]L
MG#='<R./GX=TWI"O)IE-^$%..\_JCJ2!TFPI9.SLZB"UG;BWP@O&;KEN+ZY:
M&J00V#OFPG$C'Y;HY6L#!(SZH:1U]J6CD*_-^S-9F&TM04;2L7MZBQ%DI((9
M43JWRTK,:.ZR&5&Z^>:"2)[XIF.BFB>^*:)W8Z*6)RQR1N_]YCVN:[VHIZE^
M29\IEE>C3K^QF'5;&8T5J>&KC]:8*L]K;$\%.29V/R^.25S8ERF(=9L]2R1S
M&V:UJU5=(Q9&N2S73O8=FT-FSJI6]="4+ZHZI*<H:IP3Y:RKE/<UX.6ZFUKJ
M53ZN^D%>S=IU77^339"=%TM/O<9Z-3:T;TC9".]WJ.KXM:/: @^4>C%TX.%?
M&+&5\GP]UIA<]U\*328N.W%7SU+9C7R1Y#!V'1Y.H^'FY)>LK)&UZ.:DCN5=
MOJXJE?CV53==L)USB])0G%QDFNYQ:31<''R:[H1LJLA;7))QG7)3C)/BFI1;
M3X>LX53^8UKK7$:<Q.2SV?R5+#X7#T[&1RF5R-B*I1H4:L;I;%JU8F<R.&&*
M-KG.>Y439-DW79#X]Z5GE*."W!BG9FUSKK#5,C71R-TYC[,65U+8F;R[01X6
MBZ:W%([F14=;96BY4<[K-FJ8)_E5_+6:TZ15B736'KS:.X55K$<M73B2H_+Y
M^:!=X\AJJY"_J941^TM3"U4]Q451JS3Y&RQMEG6=%^A.9M*R.E<JL;5.S(G%
MJ.[KQ52>G:3:Y)>2OARBM->.Z6=/<+9=<D[(796C5>-"2<M[N=NFO907-N6D
MFM=R,GR\5\I89-:MS1KS1S6[4L;MG-YHY9Y)(W<KD:YO,QR+LYJ.3?9R(NZ&
M0?YL)]DU:^];J_Z:TB8\1D.^;"?9-6OO6ZO^FM(EBNFWHG.^C6?J163H!Z:V
M;](7[,C89@ J&73!BV^=7_6?X???!_\ U)?,I(QB/.I,!/-P0T9D6(BU\?Q&
MI0S]^Z/OX7+I![$3>M)OO[-CK>@DDMKX&O#W_3ZW&27Y6TCC>L*+>Q-I)+7]
M[2?U*46_R)-F!,;$CS9R[%)T7\;$Q_-)7UMK)LS=G)R.DR+)6(JJB(O-&YKO
M>JJ)OLNRHJ&NW,MKS:3RB>C]%P:HX/ZZSM+3J9C+-U)H_*9BU'3Q4UF6K#5R
MN$?=L.CJT[+G5XLA3]T/C2XLUN-DG60QQNG?K0V?9D;*EV493E3=7=*,5K+<
MBIPDTEQ>ZI[STY1BWR3*^=4^TZL;:\>UE&$;Z+:(RDU&*G*5=D4V^"WG7NQU
MYR:2XM&;L-S\US_&;2&)HKE,KJK3>-QJ,21<A?SF,J4N16\Z/]U6+,<'*K/?
M([GV5%W3=#RBS_ER^$60XGZ(X2\.+,G$34FK]34<%8R>*<^OIC!5IGJZY=GR
MTD+UR$U>".=8:F.KSQR3,:EBW5A<DQ6S#V3DY&_V-%DU7&4[)*+W(0@G*4IS
M>D8I)/FUKIHM7P+1YFV,7'W%=D55NR<:ZXRFM^R<VHQC""UE-MM+2*?/CP/:
M< &N-D:X?SB;HQ3Z!Z1^>U!!6ZG \3Z-+6&-D8Q6P)E8ZM?$ZHJ\RHG/87*5
M$S5A4W3;.QHCE5'M;X7T[UBK-!:J6)JENK-%9J6J[UCL5;4$C9:]F"1JHZ.:
MO,QDL4C51S)&-<BHJ&RH\N-Y/F7COP>NK@*J6->Z%=8U+I*)J,27*]3"J9;3
MJ/<K$Y\M1:]*"/<D?U4AIMD6..225FM2FA?&]\4L<D4L;WQRPS1OBFBEC<K)
M(I8I&M?%+&]KF21O:U['M<QS4<U4+4]76WHYNS:H-IWXL8X]L>]QA%*J>GA.
MM)-OG.,RH76;T>E@;3NLC%JC,E+)IDN6]-ZW5Z\DX6:R4>ZN<#:C>3%Z;F+X
M]<']+:UK3P?5^.A6Q&M<;%[U^+U9CZ\<.5C2%RJYE*[,U<EBW[O:^A:A:Z19
MXYV1^@YJNO)Q^4@UOT;M:,U'IM4RNG\DZ&#5VCK<SXL=J'',54YHYD;(N-S-
M)KW2XO*Q1OZF5&PW(+F/DL5)=@IT//*X\#.-&-JS:?UGC,-G)61I:TEJBY4P
MN?J6'<K5@9!;F9#D/V17,BEQTUEDR,5[-FD,]->@V1@7V6TU2LP[).4)03EV
M.KU[*Q)-QW==(S?DRCIQWMZ*G+H'T_QMHX]=5]L*LZN*A9"<E'MG%)=K4Y/2
M6]SG%/>A+7AN[LGZ8@I]:WEY]TY-N;FW3EY=M^;F[MMNW??;;MWV//WI1>5+
MX%<(:<\VKN(.#=D(F.6/3^#MPYW4%B1JHG4LQF,?8EA>KE3MMK78C=WN<C&J
MIPN+AW7S5=-5ELV]%"N$IR?U139(.7G4X\'9?;736EJYV3C"*7MDTCT%W"*:
M^;I&><F\7-1<3=/:JT-4@TGH72>1EGIZ(N/;<=JRK,V2I9=K.Y K4=8L497L
MIU,:]*N#LN]T0V,A8C2R[-7Z#G38T9Q[T#C->:-M*L5A/<N9P]ET:933N:A1
M/=>)R<#'/ZN6-R]96G:JP7:;X;==[XI45.BV[T,SMG4TWY$([EO"6Y+?[&S5
MZ5VM>2I2BM4XMQ?&*;:9S'1[IUL_:=]^/BV-V4\8[\=SMZ]%K;2GY3C&3W9)
MJ,EPDX[LDS[# !RAV(,=3SG_ .QJJ_?+TE_N.?,BLQU/.?\ [&JK]\O27^XY
M\Z7H;Z5V?]*I_;1R_3;T1M+Z%D?9R->T9]?FM'UBM3_? R7T?0,!0SZ_-:/K
M%:G^^!DOH^@3UUK^B)?2*/[Y7CJ?],Q^C9']PR90 5@+7@  'GEY57HJNXR<
M!>(>BZE5MO.NPEC-Z4B5&\[M4X!CLGAJ\;G.:V)V1L0+BG3.W2&*_+)LO*B&
MJY:OH5KFJG>U[5:]JIWM>U=E:]J^]<U4W:Y%14W0W*2IOX[S6'>6PZ*#>$?2
M&UIBZ==T&!U3/^KC )RN2-*NH9IK&0KPN5&M<RIF6WXFM8UL<+%C@8G+&3=U
M/[:TEDX$GYVF35[8I0NC]<>SDDNZ,WWD!]=NP]88VT8+S-<:_P"3)N=,O4HR
M[2+\7."\3[2\F)Y3:UPMZ,'2+TDW)>YL]C*=6]PZWFY+$66UXY=,VY<<B)N^
M7"SM34<B<S&M;!LWWTFZXY;(T:U&IW-1$]?<B)^+T[_.I51RHBHBJB+MNB*J
M(NW=NB=B[=NVZ=BKV;%*9Z-8YSNQK6JY5]2-3=?P$R8&QZL>W+N@M)YEL;;.
M'?&N,-/7K)3L^59+VD(;2VS=E48=%KUA@T2IJ6NNJE9*>O+@U!UU+\6J)E?>
M:S=$A,QKC5_&7)TVR4]'X]VE=+33,C<UN?SL2.S5ZLKOV6.Q2P:-QK;$7O'0
M9O(5G+OS-,Y5#S/\D%T5'<'^C]P^TQ<JK5S]_$PZHU3$]O+-#J#4D;,G<I3H
MO_I<5'-!BI-E5BOI/<Q>5R'IB58Z:[9]W;2R;D]:X2[&GCJNRJUBFO5.6]9[
M9LMUT"V&MG[*Q:7'=MG!7W]S[:Y*4D^7&$=VOEKI!:@ '*'8@      X4Y.D
MDC6-<YSD:UJ*YSG*B-:UJ;JY57L1$1%557L1$[0##\\ZMZ5"5L9P]X,XZRJ3
MY::?7FJ(F2N:K<9CY),5IFK-&F[98K^3^J]W9W*L,V!KN:CDF][A:=QZ,^5F
MZ3CN+?2 XB:KBG]T8JMEG:9P#D39C<)IOFQE98]G.:K;$\5JWSLV;,ZPLR)^
MR*J_(/ 3A!>X@ZXTCH;&H];NK=18G 0K'R]9&F1N15Y9F<V[4=! Z29%<G*B
ML]]V;ENNB&S8[/V5CPFMQQJ>1?)]TYKM;&_D1:K]D%STU*8=-=J3VEM?)G#R
MT[UBXR7)PK?8U[OSD]9_*F^[33/A\VTZ+#]#]'V/5>3J-CR_%/-V-5)UC$ZZ
M/3E2)N(TS"_=.58[$%>]G:RHKEZG.M:Y6N16-R#/<</_ .2C_P#AM_(?R'#/
M0&.TIIW!:8Q,+(,9I_$X_#4(8V)&R.ICJL52!&L:JM8G5Q-7E:NS=]D[#^X*
MM;;VI+,R\C*EKK=;*:7Q8ZZ0C_-@HQ^HMSL'9<<'#QL2/*BF$&_C32UG+^?-
MRE]9&]QP_P#Y*/\ ^&W\@]QP_P#Y*/\ ^&W\A)!J]6;8C>XX?_R4?_PV_D(U
MW#5+,,U>Q6@FKV(I()X9(8WQ30S,6.6*1CFJU\<D;G,>QR*US55%144N0&\_
M%AHU-OE .C=9X1\:.)'#Z>-T=?!:HONPKW)^^--Y5S<QINSNC6L=))A+])MG
MJMV17&6:Z+O"Y$H= _I,R\'>+V@N(J231T=/9^H_.-AYW.FTY<5:.>C6*/9U
MA68VQ/9AK]TMJO71>U$5,C[SJKHOI5S7#_C!1@<C<I5FT/GY&L56]?06?*8&
M:5S6HUG-#-DZR.>Y7R[1M:J)$U%Q"'(BHJ+W*FWREN^CF=#:FRZIV^4KJ'3D
M1\9J+JN\=-YIR7-I27,I9TFV?/9.V+X5/1T9$<C&?XC:NIUTTUW=5%\M7%Z<
M#<C4+L-F&&S7ECGKV(HYX)HGMDBEAF:DD4L<C%5KV2,<U['-56N:J.1514)A
MXV>0<Z3Z<2^C?HIMFPD^:T-7_4%ET61'S(FG8XZV'EG3M<UT^$^IZ\SU<^9S
M'S.7>39/9,JCM/!EBY%^//SJ+9UM\M=R32DO5))27J:+A[)VC#+QL?*K\R^J
MNU+GIOQ3<7ZXO6+]:8,-CSKKH]32)PNXJU*_-'6;D]"9R=C'.<V.>1<UI]TS
MD3:*"&=,W"USEV=/?C8BHJHCLR<^-NG[T2L=QPX2ZQX<7G1PSYK&R282]*U%
M;C-1T=[6#ON]ZY>JAOQQ,M(UJO?3DL,C5DCFO;M>B6V%@[0QLF3TKC/<M^:L
M3KF]._=C+?2\8K3B:?IGL1[1V9E8L4G9*O?IU_#5-65KU;TH[C?A)]VIJ>#-
MW\UZZ<5+(:3S' ;,W61Y;35K):ET9!*_9UO3^5N/NYVC515V5V,S5J?)21-3
MGY,O)+VL;LS"TU]H+,Z5SF7TSJ/'3XG/X'(VL3F,;:;RS4\A2E=#8A=WM>SF
M;SPS1N=#8@='8@?)#+&]UVX2\5]0Z$U-@]8Z3R<^'U'IS(0Y/$9*NJ))7LPJ
MJ*U[%]Y/6L1.DK7*DJ.@MU)9JT['Q2O:MG^E&PJ]J8-E"E%.2C;1:O*C&R*;
MA+ASA)2<6UKY$VUQ*G]$^D-FR-H5Y.Y)J&]3D4O6,G5)I61::X3@XJ<4]/+@
MHO@V;@U%.3'N\G;YP=PJXI8NAA^(V2Q_#7B!'%#7O19>=*>E<S:1&L=<PF8L
M/=!4CG<JR/H96:O/45'LZVQ$D=B3W7P_%'3.0JLO4-18*[2>U7LN5,OC[-5[
M43F5S;$%A\+FHBHJJCU1$7?N*H[3V+E8=DJLBBRN47WQ;C)?&A-:QG%]SBVB
MX.RMO8>;5&[&R*[822?"24H_BS@])0DN]229_='P_P"4DXRZ=T)P+XH9_4^0
M9C\<FC\UBH'*G//<RN;HS8G$8RE#NCI[F0R-RO6@C16L:KW33/BK1331_P #
MTHO*R\!.$M">SJ/B%@K^1CC>Z#3VFKM;4.=MR-[$@93QLTS:[W.Y45UZ6K'&
MCDD>Y&>^,"CRI/E8]9]);4,26J[M-</L';EETMH^*PL[VN5JPIF=066\L5_.
MV(G2(UL,;*>*@F=0IK9<EC(W>JZ'="<O.R*K)USIQ:YQG.Z<7'?49)]G4I+R
MY2TTWDG&"U<GKI&7(=..GN'L_&MKA;"_,LA*%=%<HR<'.+2LNW6]R$==='Y4
MWI&*TUE'R>KMY6,:O>C41?A1-C)1\U@^R0U3]Y+5G]>^&!C9[>/D_(9)GFL'
MV2&J?O):L_KWPP)^Z<>B,_YB7ZXE=^KGTUL_YY_93-@* "H9<X\!_.5,1-:Z
M+V8?"U7-HZQT==G5&JO+ R_+"YSMOVJ(Z=F[E[$W1/2AKIS:X^4CZ.D_%C@5
MQ.T'18DF6S.E;[\$Q>1J2:@Q:-R^"@61Z+U,=K*4:M2>9J<S*]B941?VJZI!
M\<D;G1S120S1N='-#*QT<T,K'*R2*6-Z-?')$]%9(QZ(YCVN8Y$<BH6+ZH,N
M,L#(HX;]>2YM=^[;7!1?L;KFOJ*Q]=F'..T,:]Z[EN(JXO3AOU6V.2U\=+8/
MZT;!'S7[7N/R'1XR&#KRHN1T[KW/-R,&_OHH\M#1O4953T-GCZU&_P 2Y453
M(]-7OY*'RF.;Z-7$#ZL)6DS.A]1I6QVM]/L=RV):,<BK7S6'<JI&S-X=9'RP
MQ2[5\G5=8QL[JSYJV0H;%KHP]-_A7QBQ=?)\/=9X7/+-"V:7%QVX8,]0W8CW
MQY#"3.9DJCXMU9(Y]?JN=KVLE?R.5([ZQNC.1C9U^5N2GC9,W=&V*;C"4^,Z
M[&EY#4M7'7A*+6C;4DI,ZL.E6-E;/Q\3?C#*Q*XTRIDTI3A#A7;6F_+C*.BE
MIQC---).#E]7 X/AOI5>4BX+\&J=F;7.N\+2OP,D5NGJ%J+*:DL2,3LABPM%
MTUR-[U148ZU'7B56O3K/>.VX#&Q;;IJNFN=MDN$85Q<Y/ZHILD?*S*J(.RZV
MNJN*U<[)QA%+URDTCZUX@ZOQ> P>7S6;R%3%8C%XZW=R.2OSQUJ=*I7@?)-8
ML3RJUD<<;$W57+V]B)NJHAJ$^)68K9'4NI,A3DZZGD-09N]4F1DD:35;>3M6
M*\J,E9'*Q)(9&/1LC&/:CMG-:Y'-3V!\JKY:W6G2+DDTQB:LNC>%=>RR:OIQ
M)DDRVH)H).>M?U7;A>M>3JW(R6KA::NHTY6I++8R%AL<T7B2B%D^KCHC=LZJ
MVW):5V1N:TIIJJ,-YQ4I)M.R3GQ46XQ2TU;;W:L]9W3.C:MU-6*M['Q=]J]J
M47;.>ZGN1>C5<5'1.2WI-MZ126][_P#FT'V45'[W^L_Z6&-BD:ZWS:#[**C]
M[_6?]+#&Q2(SZV_2L?HM/[=I+'4WZ'?TN_\ 56"VYG]YV_\ -I_]DXN1;<S^
M\[?^;3_[)Q&*YHE9\F:<_*?ONY_GEO\ WB4](O(W\9].</ND[PBU;JW(QXC3
MU#+Y_'WLG,URUZ4NI=$ZGTKC)K3FHO4U$RV;H-N6G[0TJKIK=AS(()'M\W<I
M^^[G^>6_]XE+>YNZ*B[*BILJ*FZ*B^CX/67:S\..1CW8\FU&^FRF3CIO*-L'
M"36NJU2DVM5IJ4,V9GSQ<C'R:U&4\>VJZ,9:[KE5.,TGIH]&UH]&;DR"PR5C
M)(WMDCD:U\<C'(]CV/1',>Q[55KF.:J*UR*J.145%5"L8"?DG/."\UPIJ4>'
MO%^/(:KT!62*MA-1UD?:U1I*NG*SW'9B>]5S^!A8B.K0MY,MCOV2.*7(5G5Z
ME/,]X%].CA!Q*IP7=$\1=)YQL[>9*D.9IP92)41O,V?%6I8,A"K'/1CE?61B
M/W:CE5%*F](NA^;LVR4;:I3JU\C(KBY53CW:M+R)>,):-/73>CI)W&Z-=-<#
M:E494VQA=HNTQK)1C=7+O2BWY<?BSAK%KGI+6*^KSA3\>X@=(70>E*C[^IM9
MZ6P--C'2+/EL]C*+7-:BJO5)8LL=,Y>5R-9$U[W*G*UKG=ABO>5=\XOP:X3)
M\/\ H^W7Y+)Y..6CF.)"PS0T,31E:Z.Q#I2&=D4E[*VF.Y&9B9C:>-B5[JT%
MN[)%-1\FQ.C69M"V-6/3-IM*5LHM55KOE.>FB27<M92Y13? ]NWNE.%LZF5N
M3=!-)[E491=ULNZ-<-=6WXO2,5QDTN)Y(><-=-"MQ7X[38'"6V6]+<*Z$ND\
M?/"]DM:]J&>=MO5F2KR,3WT7NJ*AA&JCGQ2)@5M0/6.UV^#SGHUJJ[L1J*JK
MZ-D_(B%6:9[W/DD>^221SGR22.5\DDCW*Y[WO<JN>][E5SWN57.<JN55<J[^
MK_D8^@K8X[<;,)C;E2271NCWUM5ZVL\G^#)1IV47%XB21S71)8SV1B2"*LY'
M/GHULG*D;H:MAS+4TPQ]D;.46]*<*CRI<G/=6LGX;]UC;2^//0J#?9D;9VI*
M26N1G9&D8\U",GI%:Z>934DF^Z$-69VWD<>CA9X6]&_AAIG)5UK9JUA9-49V
M%[>2>'*ZMNV-0RT[2=WNG%5\A6Q$G+NW_P GILYZ?LCO3DIPQ-C8V-C48QC6
ML8UJ;-:UJ(C6M1.Q$1$1$1.Y$*A4//S)9%]V1/S[[;+9>&]9)R:7J3>B]1=/
M9V%#&QZ,>OS**JZ8>.[7!03?K:6K?>^( .%4\A[#4@=,OZ\?%_[ZW$C^NF;/
MH[R0-V*OTGN"<LSTCC_5K!%S.WVZR?'9&"%O8B]LDTD<;?\ WGIOLFZI^$=.
MK"SXWCCQIH66\LU3BYQ*B?V*B/1-:9MT<K$<B+U<\3F31*J(KHI&.5$WV/R+
M@MQ5OZ$UEI/6V+C;/D-(:EPFI:E9\CHHK<V$R-;()2GD8BN9!=; M2=41RI!
M,_9%WV+FV8[OV<ZH\[L-UQY::V4.*Y^TH[[K6/M3MI>;3M#M)>RO)WWRU[HO
MD;@8'RET:.FUPQXM:;QVIM%:NPN1K7J<%J;'OR-.',XF25K5EI9?%OF2U1MU
M97+7F9+'U:RM7J9)6*U[OX#I*^4OX'<)J5BUK'B)IVO:@8YS<)C+T&:U!8>W
M_P!##A\8^S<25W;R),R%CN5VS_>KM4".S,AVNA47.Y2W74JYN:DGIHXI:\_4
M73EM7%52O>12J'%25KM@JW%K5-3;W=&O6?=>YR?"'D\^G%4Z0>A[?$+$Z>O:
M>T_)J++8;!192Q#-DLA3Q#XZTV0MQ5VK7IOENI9C94ALW.KBB8Z2QUKWQ1?=
MY^.5BV463IMCN65R<)QU3<9+G%Z-K5/@^/!\#]\3+KOJA=5+?JLBIUS2:4HO
MBI+5)Z-<4].*T:X,&M4\X3^RVXF_YGH3^HFGS95FM4\X3^RVXF_YGH3^HFGR
M3NI_TG=]!M^WQB)NNST5C_\ J%7]FRSQ*RW[UL_YO-_LW&Y2QG[VK_Q$7^S:
M::W+?O6S_F\W^S<;E+&?O:O_ !$7^S:;_KIY;-_VS_\ %-%U&<MJ>W#_ %91
M. !!1/P.%.0 :X;SB'HJOX<](K,YZI6ZK3_%&E!K/'.8W:&/,(UF.U731>SF
MF^JD#,W+LG*V//0L:Y>1S6>0O1]XRW^'>NM(Z[Q:S)=TEJ#&9R-D#D9+/%2L
MLDMU&.56\JW:?NBIS*J(B3*NZ;*J9YWG*O19;K7@.NM:<"/R_"_*PYSK&HU)
M%P.1='C,U$KME>Z./KJEUT;>S>MUKE1L6Z:])$^8M5T!VHL_9-4+-).J$L2Z
M+[XPBHQU^53*&KXZO>94#K&V5+9VV;9U:PC;..=1)<-V4YN4MU_BWQGHNY;J
M]9ZL^6CZ857C5Q]U/J+#9!N1TGA*>)TKI.:%SG5I,?C*,4V4M0*J\DK+NI+>
M9FALL:B6*+:.ZO;&Q3\6\F9T6%XR<<- :%EK^Z<3:S$65U(QS$DB73F$5,EE
M8IVN['0W(H68^5.Q59;W3MV/A$S+_-4.BNYL/$3C-DH$VGEK:!TJZ1B<W)62
M/+:HNQJ]BJK))IL)CJ\T+V[/IY:"1'(J(WT](,BO9&QIJKR>PQXXU#?G.R25
M<)<-$YIMVR:YN,F>;HWB6;:VY7*Y;W;Y,\K(7'=5<&[906K;4'I&F*UX*44N
MXS'(H6QM:QC4:UC6M8U.YK6HC6HGL1$V1"J 5,+D   'P7Y3KHU+Q<X#\2M"
M0Q)-D,GI^2[A&JJ-Y<_@;$&=P;D=NBM3ZJ8ZJV1$5%?&Y\:JK7JBZJ::"2)[
MXIHGP3Q/?%-#*U62PS1.5DL4K'(CF21/:YCVN1%:YJHJ(IN3-O2:YKR_OD[[
M/!WBQ;UIA*BMX>\3KUG+XQ\4>T.$U/*U;&?T],K(V1L;/86;,XA$1%6C9EJ+
MUDF.EFFFGJAV]&NR_9]DDE<^WH3[[(Q4;8+\:5<8R7JKEWZ$$]=/1Z5E=&TJ
MX[W8+L,G1<53*3E5-]^["R4XOGH[8O334LGF_?3CI<&^-OU,U#=;2TAQ-H5=
M*Y:Q*[DJT<W6MNL:5RME=VHD<%FUD<4Y[MVQ19N65?VB;;']BHJ(J+NBINBI
MLJ*B]RHJ>OO--<Y$<BHO<O?\'XC+X\D9YP_5TYB<5PSX^V;+\?C(:N-TUQ'9
M%8NV(:4:]3!C]8QM=-8G]R1K%%6SU:-7>Y(4;E8GSQNOV-OUE]";<J2VAAP=
MEBA&%],5K.<8<(VP7.4HQTA**\IQ47'71HTO57T\IQ8/9N;-55.<IXU\WI76
MY<9TV-\(1<M9PF]([TI*36L69K8/RGA/QTT9KO'LRFC-58#5%!\;9$LX/*TL
MBUC7[<J3MK3225W]J(L<[(Y&KV.:B]A_3:UX@X'35)^2U'F\1@,<S]O?S>3I
M8JDQ?_?M7IX(&[=G?(A <J9J6XX24]=-QQ:EKX;NFNOJT+%QO@X[ZG%PTUWU
M)..GCO)Z:>O4_L#A%,:ORA?G'?#;0&/N8/A!+3XDZWDCFAAR+$G71>"F39C;
M-^ZQU>;,R1NZQ68_%2-9(^-.OO5HI(WO\_\ R,?E[=0V=8S</./6H?JG2UAE
MI[&F=:W^IK_4/.Y*=9$T]D$BCC@BP-^9ZQXB;]C9B+/5T7(ZI8C?3ZZCH'M*
M>'9F=@X0K6\JIZQOL@O.G"MK72*XZ2W7-:N"EIQXR_K$V5#-JP?="G.Q[KMK
MTECU3?"$++4]W>F^'D[R@]%-QUX9JH.$7?X/0OK.3C3N
M
M
M
M
M
M
M
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MWX[LO(IKA+6/'3RHOOY'?=!MCW8&S,;$R%%75=KOJ$M^/EW636DM%KY,EW(
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MV?=#-S+NTR:VW553*2IK<EHY3FU&5LM&UNZ1K6KU5G!KA#D B<F0&.IYS_\
M8U5?OEZ2_P!QSYD5GQAT[^@OI'I#:'CT#K7(:BQN&CSF.S[;&F+F.HY);F,B
MN0P1+/E,3F:WN9[;LJS,2FDKG-C5DT>SD=N>CN=7C9^)D6ZJNF^NR;BM7NQD
MF]%WO3N-)TEP+,K9^;C5).V_&MJK4GNK?G!QCJ^Y:OBS4_&?7YK1]8K4_P!\
M#)?1] D_K5KH\?Y7<9/])-'_ /()Z[= GR?^C.CII.]H[1&2U-D\7D,Q/FYI
MM4W<9>O-M3PPP/CBFQ>'PL#:Z-A8K6OK22(Y7*LKD5$25.G?3O9^T-GRQL:5
MSM=U4_+JW([L-[7CO/Q(BZO>K[:6S=HQR<J-"J5-M>M=V_+>GNZ>3NQX<'Q/
MN8 $)$\    Q:_.CNB8[4G#/2W%C&5N?)\.LL_%YQT;5ZR726IW0PK,]6,<^
M7ZD9ZOC9(FN='%7IY++V7/3;9V4H8\OG)_2O9H+@*NC*<S&YWBQDUTW#$JM5
M[--XYD61U3=1COV\;8G8W$.5OOHI<W7E3?D.JZ$671VK@^YUK8[E%KN=4DU=
MKX)4N;;T>FFJ6J.0Z>UX\MCYZR7NU*AR3X-JV+3HW4]-9.Y5Q2U6K>[JM37D
MGIGY'_HJ+Q?Z0&@].6:Z6<'B,@W5NI6N;O$[$:=?'>2M,CFN8Z.]?;2IR1/V
M2>&::-%W79?,PSA_-7>BDN(T5K;C%D8%2UK+),TIII[V]K=/:;ED?E[<+D[V
M9/4$SJ<J.1>5VG(W1\J2OY[(].-L>XMFY-J>[9*/8T^+LN\E->N$-^S^85>Z
M!;%]W[5Q*7'6J$^WNX:KLJ?+:E^+.>Y5R^&98[41$1$39$[$1.Y$3NV.P!40
MN@         #S3\KSTJ7\'NCWQ$U93F6#.VL4FE],*QR-F34.J)&X:E;@YO>
MN?AXK-G.R,<J=97Q<S&\SU:QWI8>?OE _)S:-Z2.!P6F];Y[6>(Q.!RLN:AK
MZ1R6(QWNZZ^J^I$[(KE<#G&SLJQ2RNJMA;7=')+(YSWHJ(FSV+/'CEX\\K7W
M/"V$[5&.\Y0@]YPW>&N_INOP3U[C5;=AD3P\F&)N^Z9TSA2Y2W%&<UNJ;EH]
M-S7?7#BUIWFJLC8C41J=S41J;]J[(FW:OQ=OQ[[&2;YL9T7EU=QNRG$._623
M$\,-/SRTI'L56.U7J=LN*QW)S(L<BTL*F>L2)VR5YYL;.G(KHW+[5_K5KH\?
MY6\9/])-'_\ ()ZW= 'R>&@^CAI?*:5T'8U!>J9G,/S>1OZFN8^]E;%MU:&I
M'&Z?&XK#UO<]>O79' Q*G.B<SGR2.<JDS]*^LK"R,#(HQ)7.Z^/9>76X15<V
ME:]=Y\Z]Z*7XVO<03T.ZJ\_&VCC9&:J%1CR=ND+>T<K(+6I:;JY6;L]>[=TY
MM'W<AR 0*6+      /-3RO/19?Q@Z/?$72=.O[HSM;$+J?3#6HU97ZATN],S
M1J0J]48Q^7CK6<&Z1_9'#DY7]BHBIJUF/YFHJ>E-]E394]BHO<J=J*B^I?4;
ME%[&N:K7(CFN16N:Y$5'-5-E147L5%3L5%[%0QS=<>;"]'O.YO,9N34/%;'2
MYG*9#*RT,9J#2L..IRY&W-<EK4(;&B+4\-.&29S*T,MF=T4*,C65R-125^KS
MIOC[.IR,?+=BKE8K:7"#GI)QW+(M:K1-1K<?6I>)#G69T R=J78^3A*OM8UR
MIN5D]Q.$9;U33T>K3G8GPXIQX^3Q\8_-=.E5^IOBOJ/A3D+*LQW$7"RY3!PN
M7]C356EH)+DT,;$1$1^0TU]4II97.79,%7B:W>7<ST$/ #@%YN1P4X:ZUTQK
M[3.L>+D>>TEF*N:QGNK4&DIJ<EBJY=Z]R&+0T$DU.U$Z2M;ACGA=-6EEBZQJ
M.53W_13F^G6U</-SO=6&YZ6505RG#<?:PUCO):OA*M0_G)M\SJ.KS9&=@8'N
M3.5>]5;/L77/?78STENMZ+1QL=FG#S6DN1R #C#NS&@\N=Y%JQQCA7BGPMIU
M8^)F,JK'GL$KV58M=8NK#M E>542&+4]!K.KI26'1P9.NY*5J>"2*K,S HU+
MIK)87)7</F*%S%Y7&V'U,AC<A7EJ7J5J-=I*]JM,UDL,C>Q>5[4W14<U5:YJ
MKN-5/.?IK^2IX*<?(W3:ZTMU6H&0]34UCIVRN$U34;V[)[NACEJY*-B*O5U<
M[0RM*-7<[*S9$:])7Z&=94L&$<7,C.[&CPKLAH[:5W0:DTK*UW+53@N"WHJ,
M%#O3KJMAGV2R\&4*<J?&VN>JIOE\?6*;KM?>]'";XR49.4WJQE8B]BINGJ7M
M0H+3B7M6-G_\J&9!Q7\TYM>Z7.T+Q?B]R*KE9!JW3SG68F[KRQNM8:RR.=4;
MMO-[D@15W_86GS_2\U,XLOE8R;B7H2&)57GF2AFYE8B-794B1K%<JJB-VYV[
M;[JO9VRU5UB[&E'>]V1CWN,JKE)?5V?%^QLARWJQVW&6[[@E+CIO1NQW%\N_
MM>6K[]._N,61D+6_M6HWX$1/P?H/HSH[]%'7G%.QF8M%X*?(U=.8?)9[4.7E
M5:V%P6*Q=*6]9GR60>QT<4KX8595IQ-FNW9W1Q5JTBN14R_NCUYJEH;&V*UW
MB=Q"SVJFPO:^7!Z9K1::QMI&KNL-K)R.O9=U:5-VR-HOQEMJ)O#>8[M;D5Z0
MZ'G#W3/#O(\+M(Z=J:0TCD\)>P4]73\<=>WU&1HR4+-Q]ZW'<FO99\4SY9,E
ME?JA:LV56Q<?9D?)S\SMSK8PZTHX2ED6-I.R4)0IA'7C+26[99)+S8J,8OFY
M?!?3[ ZF\VU[^<XXM:3:JA.$[[):)QCK#>KKBVVI2WI26G"''>6I+C?S(BIW
M*B*GQIOX^;<R3O-8/LD-4_>2U9_7OA@>TT?FK/1X1$:FKN,GO41$7]4FCMU1
M$3U: 1/D1$_ ?;W0%\BCPIZ.6MK^O-#YWB!D\QD=+9#2,]?567P%_&MQN2RV
M!S$\T4.+TOA;+;K+6GJ3(I'7'P-@EM,?6DD?%)#Y>DW6-LS*V?E8U,KW9=4X
M0WJ7&+;:?%[STY>!L>B'5GM7"VEB95\<?LJ;'*;A?O2TW)1X1W%KQ:UX^)[
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M#:CQ=S":@Q6/S>'R$+ZU[&96G!>H6X)&JU\5BK9CDAE8YJJBH]B]_9LICO\
M2:\V,X':NMV<GH7*:CX87;#GRKC<9-'GM+I*]$<Y8,5F%?D*+7R;NZBEF8:%
M=KW1U:$43(XV3ST<ZV:90C7M*,H6):.^J&]79I\*=<?*A-]^Y&<&]6E!:(KO
MTGZFKHV2MV7.%E4GK[FMGN65M]U=C6Y."[M]QDDDM9OB:_6.-&/9+'O'+&Y'
MQR1JK)&/:N[7,>Q4<UR*FZ.:J*B]J+N5;CG6)GV+#WV)Y.7K)[#WSS2<K6L;
MSRRJ^1_*QK6-YG+LQK6IV-1$RM]4>:A\1H97+A^*NC[L"OV8E[#9BG.UFRKS
M2=3-8B<NZ(WE:J=B[HO9LE+3?FHG$F:5OU5XJ:-I0I(U'^X\/F+D[H^]SHTD
MEKQ->G:B->JHO?NAV_W0MC:;WNV'Z.[7\G9:_P# X3[FFV]=/W/G^EQ]/R]M
MI[.)BE;(B=B=B>@^TNA/Y/[B9Q_U)!I[06"DGII.R/-:HR#):^F=/57*G76<
MGD>K>V22.-5?'C:3;.1M/Y(X*R\RO;F,='/S7C@KIJS!?U]J'5/$>Q$YC_J6
M^9FE].O<WE<K;%;$/7,6FM>G8GU;KP2Q[LL59&N5J9$_#'A3IG1>&IZ=TC@<
M3IO!8^-(J>)PM"OCJ-=C41$1E>M'''S=GOGJBO<O:YRJNYQO2#K:QX1<-GUR
MNM:X76Q<*H:_"4&U9.2\&H1UT>LEP.UZ.=3&19.,]I3C13%INBF2G;8EW2FM
M:ZXM=\7.6FJ\EZ-?G?11X)7>&_#K2.ALCJ?*:RN:9PU;%S:DS/)]4,BL',C%
MDY-U2&NQ6U:B323V4J00I9LV9^LGD^A0" ;K963E.7&4Y2G)I))RDVVTHI)<
M7R227))(L?35&N$*X+2,(QA%-N348I12;DVWP2XMMOFVV  ?F?H
M
M
M
M
M
M
M
M
M
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M^T^NI78G9XV1GSCI+)FJ:6UQ[*EO?DO5.U[K7C5X:'( (<)O
M                                                   !;<S^\[?^
M;3_[)Q<BVYG]YV_\VG_V3C*YHP^3-.?E/WW<_P \M_[Q*>NGD!_LO^#'^<Z_
M_P#";7QY%Y3]]W/\\M_[Q*>NGD!_LO\ @Q_G.O\ _P )M?%R>D_HO:'T#+_L
M]A2+H=Z5V9].Q/MH&S. !34N\
M
M
M
M
M
M
M
M
M
M
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M*\N?=QG/>D_6P #6FT
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M##LHRLW(=N13.NV%5'DTPL@U*+E.2W[=))/@JH]S4D=@ 1"34
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
3                      ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
